1: J Leukoc Biol 2002 Sep;72(3):417-28

Macrophages in gene therapy: cellular delivery vehicles and in vivo targets.

Burke B, Sumner S, Maitland N, Lewis CE.

Department of Microbiology and Immunology, University of Leicester, United Kingdom. bb14@leicester.ac.uk

The appearance and activation of macrophages are thought to be rapid events in the development of many pathological lesions, including malignant tumors, atherosclerotic plaques, and arthritic joints. This has prompted recent attempts to use macrophages as novel cellular vehicles for gene therapy, in which macrophages are genetically modified ex vivo and then reintroduced into the body with the hope that a proportion will then home to the diseased site. Here, we critically review the efficacy of various gene transfer methods (viral, bacterial, protozoan, and various chemical and physical methods) in transfecting macrophages in vitro, and the results obtained when transfected macrophages are used as gene delivery vehicles. Finally, we discuss the use of various viral and nonviral methods to transfer genes to macrophages in vivo. As will be seen, definitive evidence for the use of macrophages as gene transfer vehicles has yet to be provided and awaits detailed trafficking studies in vivo. Moreover, although methods for transfecting macrophages have improved considerably in efficiency in recent years, targeting of gene transfer specifically to macrophages in vivo remains a problem. However, possible solutions to this include placing transgenes under the control of macrophage-specific promoters to limit expression to macrophages or stably transfecting CD34(+) precursors of monocytes/macrophages and then differentiating these cells into monocytes/macrophages ex vivo. The latter approach could conceivably lead to the bone marrow precursor cells of patients with inherited genetic disorders being permanently fortified or even replaced with genetically modified cells.

PMID: 12223508 [PubMed - in process]

Display Abstract Sort Save Text Clip Add Order

L Number	Hits	Search Text	DB	Time stamp
1	0	mcarophage ADJ specific ADJ promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 12:55
7	279	cd11	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 12:54
13	5055	specific ADJ promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 12:55
19	3	mcarophage	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:02
25	14	macrophage ADJ specific ADJ promoter	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:01
31	0	weiner$.in	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:01
37	2077	weiner$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:01
43	0	weiner$.in. and mcarophage	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:02
49	1904	boyer.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:02
55	0	boyer.in. and (macrophage ADJ specific ADJ promoter)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:02
61	21300	macrophage	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:02
73	0	weiner$.in. and (macrophage ADJ specific ADJ promoter)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:03
67	45	weiner$.in. and macrophage	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:07
79	20980	gene ADJ delivery or gene ADJ therapy	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 13:08
85	13	(gene ADJ delivery or gene ADJ therapy) and (macrophage ADJ specific ADJ promoter)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 15:38

91	2	("5593972").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 15:38
97	3	("5888767").PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/09/26 15:39

Published online October 15, 1995

Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters

P Malik, WJ Krall, XJ Yu, C Zhou and DB Kohn

Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital, Los Angeles, University of Southern California School of Medicine, USA.

Gene transfer into human hematopoietic stem **cells** with expression targeted to the maturing **myelomonocytic** progeny has applications for gene therapy of genetic diseases affecting granulocytes and macrophages. We hypothesized that promoters of myeloid-specific genes that are upregulated with **myelomonocytic** differentiation would also upregulate expression of an exogenous gene in a **retroviral** vector. Moloney murine leukemia virus (MoMuLV)-based **retroviral** vectors using promoters from hematopoietic genes (CD11b, CD18, and CD34) were compared with vectors with viral promoters (MoMuLV long terminal repeat [LTR], cytomegalovirus [CMV], and simian virus 40 [SV40]). Human glucocerebrosidase (GC) cDNA was the reporter gene. HL60 **cells** were transduced with these vectors and vector-derived GC activity was compared in undifferentiated HL-60 **cells** and the same **cells** differentiated into granulocytes using dimethyl sulfoxide or monocyte/macrophages using phorbol myristate acetate. In undifferentiated HL-60 **cells**, vector-derived GC activity was the highest when it was controlled by the MoMuLV LTR. In HL-60 **cells** differentiated into granulocytes, vector-derived GC activity transcribed from the CD11b, MoMuLV LTR, and CMV promoters was equivalent to 1.7, 1.5, and 1.5 times the normal endogenous GC activity, respectively, and 0.8, 2.0, and 3.6 times the normal GC activity, respectively, in those differentiated into macrophages. With granulocytic differentiation, the CD11b promoter showed maximal induction in GC activity (8-fold); with macrophage differentiation, the CD11b promoter showed a fourfold induction in GC expression. The CD11b promoter also generated significant levels of GC activity in the **myelomonocytic** progeny of transduced CD34+ **cells**. Expression from the CD11b promoter, unlike that from the CMV or the MoMuLV LTR promoters, was relatively myelomonocyte-specific, with minimal expression observed in Jurkat T **cells** or HeLa carcinoma **cells**. The induction of expression from the CD11b promoter with differentiation in HL-60 **cells** correlates with the developmental regulation of the CD11b gene. **Retroviral**

vectors using the CD11b promoter have potential utility for gene therapy of disorders affecting the **myelomonocytic** lineage.

Volume 86, Issue 8, pp. 2993-3005, 10/15/1995

This article has been cited by other articles:

- Freeman, B. J., Roberts, M. S., Vogler, C. A., Nicholes, A., Hofling, A. A., Sands, M. S. (1999). Behavior and Therapeutic Efficacy of beta -Glucuronidase-Positive Mononuclear Phagocytes in a Murine Model of Mucopolysaccharidosis Type VII. *Blood* 94: 2142-2150 [Abstract] [Full Text]
- Worgall, S., Singh, R., Leopold, P. L., Kaner, R. J., Hackett, N. R., Topf, N., Moore, M. A.S., Crystal, R. G. (1999). Selective Expansion of Alveolar Macrophages In Vivo by Adenovirus-Mediated Transfer of the Murine Granulocyte-Macrophage Colony-Stimulating Factor cDNA. *Blood* 93: 655-666 [Abstract] [Full Text]
- Malik, P., Fisher, T. C., Barsky, L. L.W., Zeng, L., Izadi, P., Hiti, A. L., Weinberg, K. I., Coates, T. D., Meiselman, H. J., Kohn, D. B. (1998). An In Vitro Model of Human Red Blood Cell Production From Hematopoietic Progenitor **Cells**. *Blood* 91: 2664-2671 [Abstract] [Full Text]
- Tenen, D. G., Hromas, R., Licht, J. D., Zhang, D.-E. (1997). Transcription Factors, Normal Myeloid Development, and Leukemia. *Blood* 90: 489-519 [Full Text]

sections were analysed with **macrophage-specific** immunostaining. No signs of inflammation were seen in the region of fibroblast injection. This study demonstrates that FuGenc(TM)6 is a highly efficient transfection reagent that may be useful for in vitro son-viral transfection of primary human and rabbit fibroblasts and for in vivo therapeutic non-viral **gene delivery**.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:16:46 ON 26 SEP 2002)

     FILE 'MEDLINE' ENTERED AT 12:16:51 ON 26 SEP 2002
L1        125042 S MACROPHAGE
L2           958 S LYMPHNODE
L3         92203 S PROMOTER
L4           484 S MACROPHAGE SPECIFIC
L5             0 S L2 (S) L3 (S) L4
L6            37 S L3 (S) L4
L7             0 S L2 (L) L3 (L) L4
L8             0 S L7 NOT PY>1999
L9             0 S L7 NOT PY>2000
L10           24 S L6 NOT PY>1999
L11           20 S L6 NOT PY>1998
L12            4 S CD156
L13            0 S CD156 PROMOTER
L14            1 S L12 AND L3

     FILE 'MEDLINE, CAPLUS, BIOSIS, PCTFULL, EMBASE, USPATFULL' ENTERED AT
     12:26:17 ON 26 SEP 2002

     FILE 'MEDLINE, CAPLUS, BIOSIS, PCTFULL, EMBASE, USPATFULL, CONFSCI,
     SCISEARCH' ENTERED AT 12:26:29 ON 26 SEP 2002
L15            0 S L5
L16        21800 S GENE DELIVERY
L17            0 S L2 (S) L16
L18           28 S L2 (L) L16
L19            0 S L2 (L) L16 (L) L4
L20            0 S L18 AND L4
L21           16 S L14
L22            1 S L2 AND L4
L23            0 S IBIB ABS
L24           28 DUP REM L18 (0 DUPLICATES REMOVED)
L25           37 S L4 AND L16
L26           32 S L4 (L) L16
L27            6 S L4 (S) L16

=> dup rem l24 l25
PROCESSING COMPLETED FOR L24
PROCESSING COMPLETED FOR L25
L28           61 DUP REM L24 L25 (4 DUPLICATES REMOVED)

=> d l28 1-61 ibib abs

L28    ANSWER 1 OF 61    PCTFULL   COPYRIGHT 2002 Univentio
ACCESSION NUMBER:        2002068647 PCTFULL  ED 20020916  EW 200236
TITLE (ENGLISH):         PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF
                         USING THE SAME
TITLE (FRENCH):          PROTEINES, POLYNUCLEOTIDES CODANT CES PROTEINES ET
                         PROCEDES D'UTILISATION CORRESPONDANTS
INVENTOR(S):             PADIGARU, Muralidhara; ALSOBROOK, John, P., II; COLMAN,
                         Steven, D.; SPYTEK, Kimberly, A.; BOLDOG, Ferenc;
                         VERNET, Corine, A., M.; LI, Li; SHENOY, Suresh; CASMAN,
                         Stacie; GUO, Xiaojia; EDINGER, Scholmit; MACDOUGALL,
```

ANSWER 1 OF 6 MEDLINE
ACCESSION NUMBER: 2002476493 IN-PROCESS
DOCUMENT NUMBER: 22211703 PubMed ID: 12223508
TITLE: Macrophages in gene therapy: cellular delivery vehicles and in vivo targets.
AUTHOR: Burke B; Sumner S; Maitland N; Lewis C E
CORPORATE SOURCE: Department of Microbiology and Immunology, University of Leicester, United Kingdom.. bb14@leicester.ac.uk
SOURCE: JOURNAL OF LEUKOCYTE BIOLOGY, (2002 Sep) 72 (3) 417-28.
Journal code: 8405628. ISSN: 0741-5400.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20020920
Last Updated on STN: 20020920

AB The appearance and activation of macrophages are thought to be rapid events in the development of many pathological lesions, including malignant tumors, atherosclerotic plaques, and arthritic joints. This has prompted recent attempts to use macrophages as novel cellular vehicles for gene therapy, in which macrophages are genetically modified ex vivo and then reintroduced into the body with the hope that a proportion will then home to the diseased site. Here, we critically review the efficacy of various gene transfer methods (viral, bacterial, protozoan, and various chemical and physical methods) in transfecting macrophages in vitro, and the results obtained when transfected macrophages are used as **gene delivery** vehicles. Finally, we discuss the use of various viral and nonviral methods to transfer genes to macrophages in vivo. As will be seen, definitive evidence for the use of macrophages as gene transfer vehicles has yet to be provided and awaits detailed trafficking studies in vivo. Moreover, although methods for transfecting macrophages have improved considerably in efficiency in recent years, targeting of gene transfer specifically to macrophages in vivo remains a problem. However, possible solutions to this include placing transgenes under the control of **macrophage-specific** promoters to limit expression to macrophages or stably transfecting CD34(+) precursors of monocytes/macrophages and then differentiating these cells into monocytes/macrophages ex vivo. The latter approach could conceivably lead to the bone marrow precursor cells of patients with inherited genetic disorders being permanently fortified or even replaced with genetically modified cells.

L27 ANSWER 2 OF 6 MEDLINE
ACCESSION NUMBER: 2000477552 MEDLINE
DOCUMENT NUMBER: 20479893 PubMed ID: 11028922
TITLE: Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo studies.
AUTHOR: Hellgren I; Drvota V; Pieper R; Enoksson S; Blomberg P; Islam K B; Sylven C
CORPORATE SOURCE: Department of Cardiology, The Clinical Research Center, Huddinge, Stockholm, Sweden.. irina.hellgren@medhs.ki.se
SOURCE: CELLULAR AND MOLECULAR LIFE SCIENCES, (2000 Aug) 57 (8-9) 1326-33.
Journal code: 9705402. ISSN: 1420-682X.
PUB. COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200011
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20001103

AB The present study was undertaken to develop an efficient non-viral

gene delivery system for cardiovascular gene therapy. We investigated transfection efficiency and toxic properties of the new transfection reagent, FuGene6, and compared it with two other transfection reagents, Tfx-50 and LipoTaxi. For in vivo experiments, the plasmid was delivered intramuscularly via transplantation of fibroblasts transfected with plasmid and FuGene6. Conditions for efficient **gene delivery** were initially studied in vitro. Human and rabbit fibroblasts were isolated from skin, cultured and transfected with phVEGF165 or pCMVbeta gal plasmids, coding for vascular endothelial growth factor (VEGF) or beta-galactosidase, respectively. The effect of the DNA amount and the DNA:transfection reagent ratio on plasmid uptake were studied. Of the transfection reagents tested, only FuGene6 provided high-efficiency and dose-dependent plasmid transfer both for cell-localised (beta-galactosidase) and secreted (VEGF) gene products. When analysed with an MTT assay, FuGene6 showed no toxicity at low doses. Optimised conditions were applied for in vivo reporter **gene delivery**. Rabbits were injected intramuscularly with ex vivo-transfected fibroblasts. As in in vitro studies, ex vivo-transfected fibroblasts showed highly efficient gene expression in vivo. Tissue sections were analysed with **macrophage-specific** immunostaining. No signs of inflammation were seen in the region of fibroblast injection. This study demonstrates that FuGene6 is a highly efficient transfection reagent that may be useful for in vitro non-viral transfection of primary human and rabbit fibroblasts and for in vivo therapeutic non-viral **gene delivery**.

L27 ANSWER 3 OF 6 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2000:452689 BIOSIS
DOCUMENT NUMBER: PREV200000452689
TITLE: Highly efficient cell-mediated gene transfer using non-viral vectors and FuGeneTM6: In vitro and in vivo studies.
AUTHOR(S): Hellgren, I. (1); Drvota, V.; Pieper, R.; Enoksson, S.; Blomberg, P.; Islam, K. B.; Sylven, C.
CORPORATE SOURCE: (1) Department of Cardiology, The Clinical Research Center, Novum, Huddinge, 5th floor, 141 86, Stockholm Sweden
SOURCE: CMLS Cellular and Molecular Life Sciences, (August, 2000) Vol. 57, No. 8-9, pp. 1326-1333. print.
ISSN: 1420-682X.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The present study was undertaken to develop an efficient non-viral **gene delivery** system for cardiovascular gene therapy. We investigated transfection efficiency and toxic properties of the new transfection reagent, FuGeneTM6, and compared it with two other transfection reagents, TfxTM-50 and LipoTaxiTM. For in vivo experiments, the plasmid was delivered intramuscularly via transplantation of fibroblasts transfected with plasmid and FuGeneTM6. Conditions for efficient **gene delivery** were initially studied in vitro. Human and rabbit fibroblasts were isolated from skin, cultured and transfected with phVEGF165 or pCMVbeta gal plasmids, coding for vascular endothelial growth factor (VEGF) or beta-galactosidase, respectively. The effect of the DNA amount in the DNA:transfection reagent ratio on plasmid uptake were studied. Of the transfection reagents tested, only FuGeneTM6 provided high-efficiency and dose-dependent plasmid transfer both for cell-localised (beta-galactosidase) and secreted (VEGF) gene products. When analysed with an MTT assay, FuGeneTM6 showed no toxicity at low doses. Optimised conditions were applied for in vivo reporter **gene delivery**. Rabbits were injected intramuscularly with ex vivo-transfected fibroblasts. As in in vitro studies, ex vivo-transfected fibroblasts showed highly efficient gene expression in vivo. Tissue sections were analysed with **macrophage-specific** immunostaining. No signs of inflammation were seen in the region of

fibroblast injection. This study demonstrates that FuGeneTM6 is a highly efficient transfection reagent that may be useful for in vitro non-viral transfection of primary human and rabbit fibroblasts and for in vivo therapeutic non-viral **gene delivery**.

L27 ANSWER 4 OF 6 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2000307240 EMBASE
TITLE: Highly efficient cell-mediated gene transfer using-non-viral vectors and FuGene(TM)6: In vitro and in vivo studies.
AUTHOR: Hellgren I.; Drvota V.; Pieper R.; Enoksson S.; Blomberg P.; Islam K.B.; Sylven C.
CORPORATE SOURCE: I. Hellgren, Department of Cardiology, Clinical Research Center, Novum, 141 86 Huddinge, Stockholm, Sweden. irina.hellgren@medhs.ki.se
SOURCE: Cellular and Molecular Life Sciences, (2000) 57/8-9 (1326-1333).
ISSN: 1420-682X CODEN: CMLSFI
COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 022 Human Genetics
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The present study was undertaken to develop an efficient non-viral **gene delivery** system for cardiovascular gene therapy. We investigated transfection efficiency and toxic properties of the new transfection reagent, FuGene(TM)6, and compared it with two other transfection reagents, Tfx(TM)-50 and LipoTaxi(TM). For in vivo experiments, the plasmid was delivered intramuscularly via transplantation of fibroblasts transfected with plasmid and FuGene(TM)6. Conditions for efficient **gene delivery** were initially studied in vitro. Human and rabbit fibroblasts were isolated from skin, cultured and transfected with phVEGF165 or pCMV.beta.gal plasmids, coding for vascular endothelial growth factor (VEGF) or .beta.-galactosidase, respectively. The effect of the DNA amount and the DNA:transfection reagent ratio on plasmid uptake were studied. Of the transfection reagents tested, only FuGene(TM)6 provided high-efficiency and dose-dependent plasmid transfer both for cell-localised (.beta.-galactosidase) and secreted (VEGF) gene products. When analysed with an MTT assay, FuGene(TM)6 showed no toxicity at low doses. Optimised conditions were applied for in vivo reporter **gene delivery**. Rabbits were injected intramuscularly with ex vivo-transfected fibroblasts. As in in vitro studies, ex vivo-transfected fibroblasts showed highly efficient gene expression in vivo. Tissue sections were analysed with **macrophage-specific** immunostaining. No signs of inflammation were seen in the region of fibroblast injection. This study demonstrates that FuGene(TM)6 is a highly efficient transfection reagent that may be useful for in vitro non-viral transfection of primary human and rabbit fibroblasts and for in vivo therapeutic non-viral **gene delivery**.

L27 ANSWER 5 OF 6 USPATFULL
ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002132237	A1	20020919	
APPLICATION INFO.:	US 2001-867701	A1	20010529	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25718

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

L27 ANSWER 6 OF 6 SCISEARCH COPYRIGHT 2002 ISI (R)
ACCESSION NUMBER: 2000:678640 SCISEARCH
THE GENUINE ARTICLE: 349YY
TITLE: Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene(TM)6: in vitro and in vivo studies
AUTHOR: Hellgren I (Reprint); Drvota V; Pieper R; Enoksson S; Blomberg P; Islam K B; Sylven C
CORPORATE SOURCE: NOVUM, CLIN RES CTR, DEPT CARDIOL, 5TH FLOOR, S-14186 HUDDINGE, SWEDEN (Reprint); HUDDINGE UNIV HOSP, DEPT VASC SURG, STOCKHOLM, SWEDEN; HUDDINGE UNIV HOSP, GENE THERAPY CTR, STOCKHOLM, SWEDEN
COUNTRY OF AUTHOR: SWEDEN
SOURCE: CELLULAR AND MOLECULAR LIFE SCIENCES, (AUG 2000) Vol. 57, No. 8-9, pp. 1326-1333.
Publisher: BIRKHAUSER VERLAG AG, VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND.
ISSN: 1420-682X.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: English
REFERENCE COUNT: 27

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB The present study was undertaken to develop an efficient non-viral **gene delivery** system for cardiovascular gene therapy. We investigated transfection efficiency and toxic properties of the new transfection reagent, FuGene(TM)6, and compared it with two other transfection reagents, Tfx(TM)-50 and LipoTaxi(TM). For in vivo experiments, the plasmid was delivered intramuscularly via transplantation of fibroblasts transfected with plasmid and FuGene(TM)6. Conditions for efficient **gene delivery** were initially studied in vitro. Human and rabbit fibroblasts were isolated from skin, cultured and transfected with phVEGF165 or pCMV beta gal plasmids, coding for vascular endothelial growth factor (VEGF) or beta-galactosidase, respectively. The effect of the DNA amount and the DNA:transfection reagent ratio on plasmid uptake were studied. Of the transfection reagents tested, only FuGene(TM)6 provided high-efficiency and dose-dependent plasmid transfer both for cell-localised (beta-galactosidase) and secreted (VEGF) gene products. When analysed with an MTT assay, FuGene(TM)6 showed no toxicity at low doses. Optimised conditions were applied for in vivo reporter **gene delivery**. Rabbits were injected intramuscularly with ex vivo-transfected fibroblasts. As in in vitro studies, ex vivo-transfected fibroblasts showed highly efficient gene expression in vivo. Tissue

John; MALYANKAR, Uriel; PATTURAJAN, Meera; SHIMKETS, Richard, A.; PENA, Carol; TCHERNEV, Velizar; ZERHUSEN, Bryan, D.; MILLETT, Isabelle; MILLER, Charles; LEPLEY, Denise, M.; SMITHSON, Glennda; BAUMGARTNER, Jason; HERRMANN, John; PEYMAN, John, A.; GORMAN, Linda; MEZES, Peter; KEKUDA, Ramesh; TAUPIER, Raymond, J., Jr.; GERLACH, Valerie; GROSSE, William, M.; LIU, Xiaohong; ELLERMAN, Karen; ROTHENBERG, Mark; STONE, David, J.; BURGESS, Catherine, E.

PATENT ASSIGNEE(S): CURAGEN CORPORATION, for all designates States except US; PADIGARU, Muralidhara, for US only; ALSOBROOK, John, P., II, for US only; COLMAN, Steven, D., for US only; SPYTEK, Kimberly, A., for US only; BOLDOG, Ferenc, for US only; VERNET, Corine, A., M., for US only; LI, Li, for US only; SHENOY, Suresh, for US only; CASMAN, Stacie, for US only; GUO, Xiaojia, for US only; EDINGER, Scholmit, for US only; MACDOUGALL, John, for US only; MALYANKAR, Uriel, for US only; PATTURAJAN, Meera, for US only; SHIMKETS, Richard, A., for US only; PENA, Carol, for US only; TCHERNEV, Velizar, for US only; ZERHUSEN, Bryan, D., for US only; MILLETT, Isabelle, for US only; MILLER, Charles, for US only; LEPLEY, Denise, M., for US only; SMITHSON, Glennda, for US only; BAUMGARTNER, Jason, for US only; HERRMANN, John, for US only; PEYMAN, John, A., for US only; GORMAN, Linda, for US only; MEZES, Peter, for US only; KEKUDA, Ramesh, for US only; TAUPIER, Raymond, J., Jr., for US only; GERLACH, Valerie, for US only; GROSSE, William, M., for US only; LIU, Xiaohong, for US only; ELLERMAN, Karen, for US only; ROTHENBERG, Mark, for US only; STONE, David, J., for US only; BURGESS, Catherine, E., for US only

AGENT: ELRIFI, Ivor, R.

LANGUAGE OF PUBL.: English

LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002068647	A2	20020906

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2002-US1311	A	20020116
PRIORITY INFO.:	US 2001-60/261,376		20010116
	US 2001-60/262,454		20010118
	US 2001-60/262,587		20010118
	US 2001-60/265,530		20010131
	US 2001-60/268,595		20010214
	US 2001-60/272,409		20010228
	US 2001-60/276,777		20010316
	US 2001-60/291,672		20010517
	US 2001-60/325,306		20010927
	US 2001-60/330,336		20011018
	US 2001-60/330,336		20011109

ABEN Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of

the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ABFR Cette invention se rapporte a des sequences d'acides nucleiques qui codent de nouveaux polypeptides. Cette invention concerne egalement des polypeptides codes par ces sequences d'acides nucleiques et des anticorps, qui se fixent de facon immunospecifique a ces polypeptides, ainsi que des derives, des variants, des mutants ou des fragments d'un tel polypeptide, polynucleotide ou anticorps. Cette invention concerne en outre des procedes therapeutiques, diagnostiques et de recherche pour le diagnostic, le traitement et la prevention d'affections impliquant l'un de ces nouveaux acides nucleiques et proteines humains.

L28 ANSWER 2 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002068444 PCTFULL ED 20020916 EW 200236

TITLE (ENGLISH): TTK IN DIAGNOSIS AND AS A THERAPEUTIC TARGET IN CANCER

TITLE (FRENCH): UTILISATION DE LA TTK A DES FINS DE DIAGNOSTIC ET COMME CIBLE THERAPEUTIQUE DU CANCER

INVENTOR(S): REINHARD, Christoph; JEFFERSON, Anne, B.; CHAN, Vivien, W.

PATENT ASSIGNEE(S): CHIRON CORPORATION, for all designates States except US; REINHARD, Christoph, for US only; JEFFERSON, Anne, B., for US only; CHAN, Vivien, W., for US only

AGENT: BLACKBURN, Robert, P.

LANGUAGE OF PUBL.: English

LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002068444	A1	20020906

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2002-US5278	A	20020221
PRIORITY INFO.:	US 2001-60/271,254		20010221

ABEN The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

ABFR La presente invention concerne, d'une part des procedes permettant d'identifier des cellules cancereuses par detection des niveaux d'expression de la TTK (Tyrosine Threonine Kinase), et d'autre part des procedes de diagnostic, de pronostic et des traitements qui exploitent les possibilites de l'expression differentielle de ces genes dans le cancer des mammiferes. Ces procedes conviennent pour determiner l'aptitude d'un sujet a reagir a une therapie particuliere, par exemple comme base d'une therapie rationnelle. L'invention concerne en outre des essais permettant d'identifier des produits pharmaceutiques qui modulent l'activite de ces genes dans le cas de cancers ou ces genes sont impliques, ainsi que des procedes permettant d'inhiber la croissance

tumorale par inhibition de l'activite de la TTK.

L28 ANSWER 3 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002066609 PCTFULL ED 20020910 EW 200235
TITLE (ENGLISH): 23565, A NOVEL HUMAN ZINC CARBOXYPEPTIDASE FAMILY MEMBER AND USES THEREOF
TITLE (FRENCH): 23565, UN MEMBRE DE LA FAMILLE DES CARBOXYPEPTIDASES A ZINC ET UTILISATIONS ASSOCIEES
INVENTOR(S): KAPELLER-LIBERMANN, Rosana; CARROLL, Joseph, M.
PATENT ASSIGNEE(S): MILLENNIUM PHARMACEUTICALS, INC., for all designates States except US; KAPELLER-LIBERMANN, Rosana, for US only; CARROLL, Joseph, M., for US only
AGENT: MYERS, P., Louis.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002066609	A2	20020829

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US4473 A 20020215
PRIORITY INFO.: US 2001-60/269,440 20010216

ABEN The invention provides isolated nucleic acids molecules, designated 23565 nucleic acid molecules, which encode novel zinc carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23565 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 23565 gene has been introduced or disrupted. The invention still further provides isolated 23565 proteins, fusion proteins, antigenic peptides and anti-23565 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

ABFR L'invention concerne des molecules isolees d'acides nucleiques, designees par 23565, qui codent pour des membres de la famille des carboxypeptidases a zinc. L'invention concerne aussi des molecules d'acides nucleiques antisens, des vecteurs d'expression recombinants contenant des molecules d'acides nucleiques 23565, des cellules hotes dans lesquelles on a introduit les vecteurs d'expression, et des animaux transgeniques non humains dans lesquels on a introduit ou fragmente un gene 23565. Elle concerne encore des proteines 23565, des proteines de fusion, des peptides antigenes et des anticorps anti-23565. Elle concerne enfin des procedes de diagnostic utilisant des compositions de l'invention.

L28 ANSWER 4 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002055700 PCTFULL ED 20020725 EW 200229
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS ISOLATED FROM HUMAN PROSTATE
TITLE (FRENCH): GENES HUMAINS ET PRODUITS D'EXPRESSION GENETIQUE ISOLES DE LA PROSTATE HUMAINE
INVENTOR(S): ESCOBEDO, Jaime; GARCIA, Pablo Dominguez; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, William Lee; STACHE-CRAIN, Birgit; SCOTT, Elizabeth, M.
PATENT ASSIGNEE(S): CHIRON CORPORATION, for all designates States except

US; HYSEQ, INC., for all designates States except US; ESCOBEDO, Jaime, for US only; GARCIA, Pablo Dominguez, for US only; KASSAM, Altaf, for US only; LAMSON, George, for US only; DRMANAC, Radoje, for US only; CRKVENJAKOV, Radomir, for US only; DICKSON, Mark, for US only; DRMANAC, Snezana, for US only; LABAT, Ivan, for US only; LESHKOWITZ, Dena, for US only; KITA, David, for US only; GARCIA, Veronica, for US only; JONES, William Lee, for US only; STACHE-CRAIN, Birgit, for US only; SCOTT, Elizabeth, M., for US only

AGENT: BOZICEVIC, Karl
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002055700	A2	20020718
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US47349	A	20011207
PRIORITY INFO.:	US 2000-60/254,648		20001207
	US 2001-60/275,688		20010313

ABEN This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostics and therapeutics comprising such novel human polynucleotides, their corresponding genes or gene products, including probes, antisense nucleotides, and antibodies. The polynucleotides of the invention correspond to a polynucleotide comprising the sequence information of at least one of SEQ ID NOS:1-1477. The polypeptides of the invention correspond to a polypeptide comprising the amino acid sequence information of at least one of SEQ ID NOS:1478-1568.

ABFR L'invention concerne de nouveaux polynucleotides humains et des variants de ceux-ci, leurs polypeptides codes et les variants de ceux-ci, des genes correspondant a ces polynucleotides et des proteines exprimees par ces genes. L'invention concerne egalement des diagnostics et therapies utilisant ces nouveaux polynucleotides humains, leurs genes correspondants ou leurs produits genetiques, y compris des sondes, des nucleotides antisens et des anticorps. Les polynucleotides decrits par la presente invention correspondent a un polynucleotide contenant les informations de sequence d'au moins une des SEQ ID NOS:1-1477. Les polypeptides decrits par la presente invention correspondent a un polypeptide comprenant des informations de sequence aminoacide d'au moins une des sequences SEQ ID NOS:1478-1568.

L28 ANSWER 5 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2002050276 PCTFULL ED 20020709 EW 200226
TITLE (ENGLISH): NOVEL PROTEIN AND NUCLEIC ACIDS ENCODING SAME
TITLE (FRENCH): NOUVELLE PROTEINE ET ACIDES NUCLEIQUES CODANT POUR CELLE-CI
INVENTOR(S): LI, Li; PADIGARU, Muralidhara; BALLINGER, Robert, A.; KEKUDA, Ramesh; COLMAN, Steven, D.; SCIORE, Paul; SMITHSON, Glennda; PEYMAN, John, A.; MACDOUGALL, John, R.; STONE, David; VERNET, Corine, A., M.; SHENOY, Suresh; GUNTHER, Erik; MILLET, Isabelle; TCHERNEV,

Velizar, T.; ANDERSON, David; GUSEV, Vladimir; MALYANKAR, Uriel, M.; ZHONG, Haihong; ELLERMAN, Karen, E.; WOLENC, Adam

PATENT ASSIGNEE(S): CURAGEN CORPORATION, for all designates States except US; LI, Li, for US only; PADIGARU, Muralidhara, for US only; BALLINGER, Robert, A., for US only; KEKUDA, Ramesh, for US only; COLMAN, Steven, D., for US only; SCIORE, Paul, for US only; SMITHSON, Glennda, for US only; PEYMAN, John, A., for US only; MACDOUGALL, John, R., for US only; STONE, David, for US only; VERNET, Corine, A., M., for US only; SHENOY, Suresh, for US only; GUNTHER, Erik, for US only; MILLET, Isabelle, for US only; TCHERNEV, Velizar, T., for US only; ANDERSON, David, for US only; GUSEV, Vladimir, for US only; MALYANKAR, Uriel, M., for US only; ZHONG, Haihong, for US only; ELLERMAN, Karen, E., for US only; WOLENC, Adam, for US only

AGENT: ELRIFI, Ivor, R.

LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002050276	A2	20020627

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US49347	A	20011218
PRIORITY INFO.:	US 2000-60/256,635		20001218
	US 2000-60/257,876		20001221
	US 2001-60/259,743		20010104
	US 2001-60/260,718		20010110
	US 2001-60/261,498		20010112
	US 2001-60/263,689		20010124
	US 2001-60/267,464		20010208
	US 2001-60/271,021		20010222
	US 2001-60/275,946		20010314
	US 2001-60/278,150		20010323
	US 2001-60/284,591		20010418
	US 2001-60/285,718		20010423
	US 2001-60/312,902		20010616
	US 2001-60/299,327		20010619

ABEN Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further disclosed therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ABFR L'invention concerne des sequences d'acides nucleiques codant pour des polypeptides associes aux recepteurs couples aux proteines G. L'invention concerne en outre des polypeptides codes par ces sequences d'acides nucleiques, des anticorps se liant de maniere immunospecifique a ces polypeptides, ainsi que des derives, des variants, des mutants ou des fragments desdits polypeptides, polynucleotides ou anticorps. Cette invention se rapporte en outre a des methodes de traitement, de

diagnostic et de recherche destinees au diagnostic, au traitement et a la prevention de troubles impliquant des acides nucleiques et des proteines de ce type.

L28 ANSWER 6 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002026826 PCTFULL ED 20020701 EW 200214

TITLE (ENGLISH): NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME

TITLE (FRENCH): NOUVELLES PROTEINES ET ACIDES NUCLEIQUES CODANT POUR CELLES-CI

INVENTOR(S): GERLACH, Valerie, L.; MACDOUGALL, John, R.; SMITHSON, Glennda; MILLET, Isabelle; STONE, David; GUNTHER, Erik; ELLERMAN, Karen; GROSSE, William, M.; ALSOBROOK, John, P., II; LEPLEY, Denise, M.; BURGESS, Catherine, E.; PADIGARU, Muralidhara; KEKUDA, Ramesha; SPYTEK, Kimberly, A.; LEACH, Martin, D.; SHIMKETS, Richard, A.

PATENT ASSIGNEE(S): CURAGEN CORPORATION, for all designates States except US; GERLACH, Valerie, L., for US only; MACDOUGALL, John, R., for US only; SMITHSON, Glennda, for US only; MILLET, Isabelle, for US only; STONE, David, for US only; GUNTHER, Erik, for US only; ELLERMAN, Karen, for US only; GROSSE, William, M., for US only; ALSOBROOK, John, P., II, for US only; LEPLEY, Denise, M., for US only; BURGESS, Catherine, E., for US only; PADIGARU, Muralidhara, for US only; KEKUDA, Ramesha, for US only; SPYTEK, Kimberly, A., for US only; LEACH, Martin, D., for US only; SHIMKETS, Richard, A., for US only

AGENT: ELRIFI, Ivor, R.

LANGUAGE OF PUBL.: English

LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002026826	A2	20020404

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US42336	A	20010927
PRIORITY INFO.:	US 2000-60/235,631		20000927
	US 2000-60/235,633		20000927
	US 2000-60/235,808		20000927
	US 2000-60/236,064		20000927
	US 2000-60/236,065		20000927
	US 2000-60/236,066		20000927
	US 2000-60/236,135		20000928
	US 2000-60/237,434		20001003
	US 2000-60/238,321		20001005
	US 2000-60/238,399		20001006
	US 2000-60/238,396		20001006
	US 2001-60/276,667		20010316
	US 2001-60/294,823		20010531
	US 2001-60/304,868		20010712
	US 2001-60/304,868		20010926

ABEN Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antiboides, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods

for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

ABFR L'invention concerne des sequences d'acides nucleiques codant pour de nouveaux polypeptides. L'invention concerne egalement des polypeptides codes par ces sequences d'acides nucleiques, et des anticorps de liaison immunospecifique aux polypeptides, ainsi que des derives, des variants, des mutants ou des fragments des polypeptides, des polynucleotides ou des anticorps mentionnes ci-dessus. L'invention concerne egalement des methodes therapeutiques, diagnostiques et de recherche utilisees dans le diagnostic, le traitement et la prevention des troubles associes a un quelconque de ces nouveaux acides nucleiques et nouvelles proteines humaines.

L28 ANSWER 7 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002024739 PCTFULL ED 20020701 EW 200213
TITLE (ENGLISH): SPAS-1 CANCER ANTIGEN
TITLE (FRENCH): ANTIGENE DU CANCER SPAS-1
INVENTOR(S): ALLISON, James, P.; FASSO, Marcella; SHASTRI, Nilabh
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
AGENT: SERAFINI, Andrew, T.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002024739	A2	20020328
DESIGNATED STATES	AU CA JP AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
APPLICATION INFO.:	WO 2001-US28621	A	20010913
PRIORITY INFO.:	US 2000-60/234,472		20000921

ABEN Compounds and methods for inducing protective immunity against cancer are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more SPAS-1 proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and pharmaceutical compositions for immunization against cancer , or can be used for the diagnosis of cancer and the monitoring of cancer progression.

ABFR L'invention concerne des composes et des methodes permettant d'activer l'immunite protectrice contre le cancer. Ces composes comprennent des polypeptides contenant au moins une portion immunogenique d'une ou de plusieurs proteines SPAS-1 et des molecules d'ADN codant pour de tels polypeptides. De tels composes peuvent etre prepares sous forme de vaccins et de compositions pharmaceutiques permettant l'immunisation contre le cancer, ou encore, ils peuvent etre utilises pour diagnostiquer un cancer et pour surveiller la progression d'un cancer.

L28 ANSWER 8 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002020762 PCTFULL ED 20020705 EW 200211
TITLE (ENGLISH): TNF RECEPTOR-LIKE MOLECULES AND USES THEREOF
TITLE (FRENCH): MOLECULES ANALOGUES AU RECEPTEUR DU TNF ET SES UTILISATIONS
INVENTOR(S): THEILL, Lars, Eyde; YEH, Richard; SILBIGER, Scott, Michael; YU, Gang; SENALDI, Giorgio
PATENT ASSIGNEE(S): AMGEN INC., for all designates States except US; THEILL, Lars, Eyde, for US only; YEH, Richard, for US only; SILBIGER, Scott, Michael, for US only; YU, Gang, for US only; SENALDI, Giorgio, for US only
AGENT: BORUN, Michael, F.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE

```
                         ---------------------------------
                         WO 2002020762          A2 20020314
DESIGNATED STATES        AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                         CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
                         IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
                         MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
                         TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
                         MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
                         CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
                         BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:       WO 2001-US27631        A  20010905
PRIORITY INFO.:          US 2000-60/230,191        20000905
```

ABEN Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.

ABFR L'invention porte sur de nouveaux polypeptides MK61 et sur les molecules d'acide nucleiques codant pour eux, sur des vecteurs, cellules hotes, agents selectifs de fixation et methodes de production des polypeptides MK61, et sur des methodes de traitement, de diagnostic, d'amelioration et de prevention de maladies dues aux polypeptides MK61.

```
L28   ANSWER 9 OF 61     PCTFULL   COPYRIGHT 2002 Univentio
ACCESSION NUMBER:        2002018948 PCTFULL  ED 20020705  EW 200210
TITLE (ENGLISH):         DIFFERENTIALLY EXPRESSED EPITOPES AND USES THEREOF
TITLE (FRENCH):          EPITOPES EXPRIMES DE MANIERE DIFFERENTIELLE ET
                         UTILISATIONS ASSOCIEES
INVENTOR(S):             LOGTENBERG, Ton; CILENTI, Lucia; BLOEM, Andries,
                         Christiaan; ZWIJSSEN, Renate, Marie, Louise
PATENT ASSIGNEE(S):      CRUCELL HOLLAND B.V., for all designates States except
                         US; LOGTENBERG, Ton, for US only; CILENTI, Lucia, for
                         US only; BLOEM, Andries, Christiaan, for US only;
                         ZWIJSSEN, Renate, Marie, Louise, for US only
AGENT:                   PRINS, A., W.
LANGUAGE OF PUBL.:       English
LANGUAGE OF FILING:      English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:

                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 2002018948          A2 20020307
DESIGNATED STATES        AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                         CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
                         IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
                         MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
                         SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS
                         MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
                         BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
                         BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.:       WO 2001-NL636          A  20010827
PRIORITY INFO.:          EP 2000-00202991.6        20000828
                         US 2000-60/228,429        20000828
```

ABEN Provided are among others novel epitopes, methods for finding these epitopes and binding molecules capable of binding to said novel epitopes. In one aspect the invention provides a binding molecule capable of specifically binding to a preferably, post-translationally modified, disease associated molecular marker, associated with diseased cells, whereas said preferably post-translationally modified disease associated molecular marker is not associated with non-diseased cells. In a preferred aspect of the invention, said binding molecule recognizes an epitope present in a subset of CD46 proteins. Said binding molecule is capable of distinguishing between CD46 proteins belonging to the subset and CD46 proteins not belonging to the subset. The binding

molecule is preferably an antibody. Medicaments and uses of binding molecules are provided.

ABFR L'invention concerne, entre autres, des nouveaux epitopes, des procedes servant a trouver ces epitopes et a lier des molecules capables de se lier a ces nouveaux epitopes. Dans l'un de ses aspects, l'invention concerne une molecule de liaison capable de se lier specifiquement a un marqueur moleculaire associe a une maladie, lequel est modifie de maniere preferablement post-translationnelle, est associe a des cellules malades, mais n'est pas associe a des cellules non malades. Dans un aspect prefere de l'invention, cette molecule de liaison reconnait un epitope present dans un sous-ensemble de proteines CD46. Cette molecule de liaison est capable de faire la distinction entre des proteines CD46 appartenant audit sous-ensemble, et des proteines CD46 n'appartenant pas a ce sous-ensemble. De preference, cette molecule de liaison est un anticorps. L'invention concerne encore des medicaments et des utilisations des molecules de liaison.

L28 ANSWER 10 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002062979 PCTFULL ED 20020827 EW 200233
TITLE (ENGLISH): ENZYME
TITLE (FRENCH): ENZYME
INVENTOR(S): GRIMSHAW, Matthew; BALKWILL, Frances
PATENT ASSIGNEE(S): OXFORD BIOMEDICA (UK) LIMITED, for all designates States except US; GRIMSHAW, Matthew, for US only; BALKWILL, Frances, for US only
AGENT: HARDING, Charles, Thomas
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002062979	A2	20020815
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2002-GB481	A	20020205
PRIORITY INFO.:	GB 2001-0102946.1		20010206

ABEN An MPK phosphatase 1 (MKP-1) enzyme for use in medicine for the hypoxic mediated inhibition of monocyte/macrophage migration is described. The MKP-1 enzyme is substantially upregulatable under hypoxic and/or inflammatory conditions.

ABFR L'invention concerne une enzyme MPK phosphatase 1 (MKP-1) destinee a etre utilisee medicalement pour l'inhibition induite par hypoxie de la migration de monocytes/macrophages. Cette enzyme MKP-1 peut etre sensiblement regulee positivement dans des conditions hypoxiques et/ou inflammatoires.

L28 ANSWER 11 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2002024897 PCTFULL ED 20020701 EW 200213
TITLE (ENGLISH): IMPROVED CONDITIONALLY REPLICATING VECTORS, METHODS FOR THEIR PRODUCTION AND USE
TITLE (FRENCH): VECTEURS AMELIORES A REPLICATION CONDITIONNELLE, PROCEDES DE PRODUCTION ET UTILISATION DE CES VECTEURS
INVENTOR(S): CHANG, Yung-Nien; LU, Xiaobin; SLEPUSHKIN, Vladimir; CONDE, Betty; DAVIS, Brian; YU, Qiao; YANG, Yanping; MERLING, Randal; HAN, Wei; NI, Yajin; LI, Yuexia; DROPULIC, Boro

PATENT ASSIGNEE(S): VIRXSYS
AGENT: LAU, Kawai
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2002024897	A2	20020328

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US29976 A 20010921
PRIORITY INFO.: US 2000-09/667,893 20000922

ABEN The present invention provides improved conditionally replicating vectors that have improved safety against the generation of replication competent vectors or virus. Also disclosed are methods of making, propagating and selectively packaging, modifying, and using such vectors. Included are improved helper constructs, host cells, for use with the improved vectors as well as pharmaceutical compositions and host cells comprising the vectors, the use of vector containing host cells to screen drugs, and methods of using the vectors to determine gene function. The methods also include the prophylatic and therapeutic treatment of disease, especially viral infection, and HIV infection in particular.

ABFR L'invention concerne des vecteurs ameliores a replication conditionnelle presentant une protection accrue contre la generation vecteurs ou virus capables de replication. L'invention concerne egalement de procedes de preparation, de propagation et d'encapsidation selective, de modification et d'utilisation de tels vecteurs. L'invention concerne notamment des assistants recombines, des cellules hotes destines a etre utilises avec ces vecteurs ameliores, ainsi que des compositions pharmaceutiques et des cellules hotes comprenant ces vecteurs, l'utilisation de cellules hotes contenant les vecteurs pour l'identification de medicaments, et des procedes consistant a utiliser ces vecteurs pour determiner une fonction genique. Les methodes decrites comprennent en outre le traitement preventif et curatif de maladies, en particulier d'infections virales et de l'infection par le VIH.

L28 ANSWER 12 OF 61 USPATFULL
ACCESSION NUMBER: 2002:119591 USPATFULL
TITLE: 16658, 14223, and 16002, novel human kinases and uses therefor
INVENTOR(S): Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061574	A1	20020523	
APPLICATION INFO.:	US 2001-922138	A1	20010803	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229299P	20000901 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA,

92130-2332
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 4922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 16658, 14223, and 16002 nucleic acid molecules, which encode novel kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16658, 14223, and 16002 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16658, 14223, and 16002 gene has been introduced or disrupted. The invention still further provides isolated 16658, 14223, and 16002 proteins, fusion proteins, antigenic peptides and anti-16658, -14223, and -16002 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 13 OF 61 USPATFULL
ACCESSION NUMBER: 2002:119590 USPATFULL
TITLE: 18431 and 32374, novel human protein kinase family members and uses therefor
INVENTOR(S): Meyers, Rachel, Newton, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061573	A1	20020523	
APPLICATION INFO.:	US 2001-916790	A1	20010727	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221543P	20000728 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 4936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated nucleic acids molecules, designated 32374 or 18431 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32374 or 18431 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 14 OF 61 USPATFULL
ACCESSION NUMBER: 2002:92878 USPATFULL
TITLE: FAS LIGAND EXPRESSING ANTIGEN PRESENTING CELLS FOR

TOLERANCE INDUCTION
INVENTOR(S): MOUNTZ, JOHN D., BIRMINGHAM, AL, UNITED STATES
ZHOU, TONG, BIRMINGHAM, AL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049404	A1	20020425
APPLICATION INFO.:	US 1998-79834	A1	19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46560P	19970515 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BENJAMIN A. ADLER, 8011 CANDLE LANE, HOUSTON, TX, 77071
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 1366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method of inducing systemic tolerance to an antigen in an individual in need of such treatment, comprising the step of: administering antigen presenting cells to said individual, wherein said cells express Fas ligand and said antigen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 15 OF 61 USPATFULL
ACCESSION NUMBER: 2002:243051 USPATFULL
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES
Jones, Robert, Seattle, WA, UNITED STATES
Harlocker, Susan L., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 25718
AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

L28 ANSWER 16 OF 61 USPATFULL
ACCESSION NUMBER: 2002:148564 USPATFULL

TITLE: 31 human secreted proteins
INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Duan, Roxanne D., Bethesda, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES
Endress, Gregory A., Potomac, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002076705	A1	20020620
APPLICATION INFO.:	US 2001-820893	A1	20010330 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-531119, filed on 20 Mar 2000, ABANDONED Continuation-in-part of Ser. No. WO 1999-US22012, filed on 22 Sep 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101546P	19980923 (60)
	US 1998-102895P	19981002 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 17043
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 17 OF 61 USPATFULL
ACCESSION NUMBER: 2002:54337 USPATFULL
TITLE: THERAPY FOR CELLULAR ACCUMULATION IN CHRONIC INFLAMMATORY DISEASES
INVENTOR(S): FIRESTEIN, GARY S., DEL MAR, CA, UNITED STATES
ZVAIFLER, NATHAN J., LA JOLLA, CA, UNITED STATES
GREEN, DOUGLAS R., SAN DIEGO, CA, UNITED STATES
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002031496	A1	20020314
APPLICATION INFO.:	US 1999-363997	A1	19990729 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-2948P	19950830 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GRAY CARY WARE & FREIDENRICH LLP, LISA A HAILE PHD, 4365 EXECUTIVE DRIVE, SUITE 1600, SAN DIEGO, CA,

921212189
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes **gene delivery** and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods for detecting cellular accumulation diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 18 OF 61 USPATFULL
ACCESSION NUMBER: 2002:152407 USPATFULL
TITLE: Methods to assay gene function with viral vectors
INVENTOR(S): Dropulic, Boro, Ellicott City, MD, United States
Pitha-Rowe, Paula, Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410257	B1	20020625
APPLICATION INFO.:	US 2000-562894		20000501 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-251085, filed on 16 Feb 1999, now patented, Pat. No. US 6114141 Continuation of Ser. No. US 1997-917625, filed on 22 Aug 1997, now patented, Pat. No. US 5888767 Division of Ser. No. US 1996-758598, filed on 27 Nov 1996, now patented, Pat. No. US 5885806

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-32800P	19951128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Wang, Andrew
ASSISTANT EXAMINER: Larson, Thomas G.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to vital vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 19 OF 61 USPATFULL
ACCESSION NUMBER: 2002:122766 USPATFULL

TITLE: Methods and compositions for combating HIV infection
INVENTOR(S): Karn, Jonathan, Cambridge, UNITED KINGDOM
Zemmel, Rodney Warren, London, UNITED KINGDOM
Butler, Peter Jonathan Gasking, Cambridge, UNITED KINGDOM
Craig, Roger K., Cheshire, UNITED KINGDOM
Irvine, Alistair Simpson, Derbyshire, UNITED KINGDOM
PATENT ASSIGNEE(S): RiboTargets Limited, Cambridge, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6395891	B1	20020528
APPLICATION INFO.:	US 1998-150812		19980911 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-839624, filed on 15 Apr 1997, now patented, Pat. No. US 6225045

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-7819	19960415
	US 1996-17268P	19960513 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Williams, Kathleen Madden, Palmer & Dodge LLP
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2742
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of cooperativity than wild-type RRE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 20 OF 61 USPATFULL
ACCESSION NUMBER: 2002:24276 USPATFULL
TITLE: Cationic lipid:DNA complexes for gene targeting
INVENTOR(S): Gorman, Cori M., San Francisco, CA, United States
McClarrinon, Molly, San Francisco, CA, United States
PATENT ASSIGNEE(S): Valentis, Inc., Burlingame, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6344446	B1	20020205
APPLICATION INFO.:	US 1998-184771		19981102 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-485005, filed on 7 Jun 1995, now patented, Pat. No. US 5830878
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: McDonnell Boehnen Hulbert & Berghoff
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention herein describes pharmaceutical compositions and methods for targeted delivery of functional genes into cells and tissues in

vivo. The invention discloses DNA:lipid complexes, methods of making such complexes and methods of using such complexes for facilitating the targeted delivery and entry of recombinant expression constructs into cells and tissues in vivo, and particularly delivery of such recombinant expression constructs by intravenous, intraperitoneal or direct injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 21 OF 61 MEDLINE
ACCESSION NUMBER: 2002476493 IN-PROCESS
DOCUMENT NUMBER: 22211703 PubMed ID: 12223508
TITLE: Macrophages in gene therapy: cellular delivery vehicles and in vivo targets.
AUTHOR: Burke B; Sumner S; Maitland N; Lewis C E
CORPORATE SOURCE: Department of Microbiology and Immunology, University of Leicester, United Kingdom.. bb14@leicester.ac.uk
SOURCE: JOURNAL OF LEUKOCYTE BIOLOGY, (2002 Sep) 72 (3) 417-28. Journal code: 8405628. ISSN: 0741-5400.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20020920
Last Updated on STN: 20020920

AB The appearance and activation of macrophages are thought to be rapid events in the development of many pathological lesions, including malignant tumors, atherosclerotic plaques, and arthritic joints. This has prompted recent attempts to use macrophages as novel cellular vehicles for gene therapy, in which macrophages are genetically modified ex vivo and then reintroduced into the body with the hope that a proportion will then home to the diseased site. Here, we critically review the efficacy of various gene transfer methods (viral, bacterial, protozoan, and various chemical and physical methods) in transfecting macrophages in vitro, and the results obtained when transfected macrophages are used as **gene delivery** vehicles. Finally, we discuss the use of various viral and nonviral methods to transfer genes to macrophages in vivo. As will be seen, definitive evidence for the use of macrophages as gene transfer vehicles has yet to be provided and awaits detailed trafficking studies in vivo. Moreover, although methods for transfecting macrophages have improved considerably in efficiency in recent years, targeting of gene transfer specifically to macrophages in vivo remains a problem. However, possible solutions to this include placing transgenes under the control of **macrophage-specific** promoters to limit expression to macrophages or stably transfecting CD34(+) precursors of monocytes/macrophages and then differentiating these cells into monocytes/macrophages ex vivo. The latter approach could conceivably lead to the bone marrow precursor cells of patients with inherited genetic disorders being permanently fortified or even replaced with genetically modified cells.

L28 ANSWER 22 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001096523 PCTFULL ED 20020826
TITLE (ENGLISH): POLYNUCLEOTIDES RELATED TO COLON CANCER
TITLE (FRENCH): POLYNUCLEOTIDES LIES AU CANCER DU COLON
INVENTOR(S): KENNEDY, Giulia, C.; KANG, Sanmao; REINHARD, Christoph; JEFFERSON, Anne, Bennet
PATENT ASSIGNEE(S): CHIRON CORPORATION; KENNEDY, Giulia, C.; KANG, Sanmao; REINHARD, Christoph; JEFFERSON, Anne, Bennet
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001096523	A2	20011220

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US19313 A 20010615
PRIORITY INFO.: US 2000-60/211,835 20000615

ABEN The present invention is based on the discovery of polynucleotides that represent genes that are differentially expressed in colon cancer, e.g., adenomatous polyp, colorectal carcinoma, high metastatic potential colon tumor and metastatic colon cancer. The invention features methods of identifying cells affected by such colon diseases by detection of a gene product encoded by such differentially expressed genes, as well as method of moduloating expression of such gene products to effect therapy (e.g., to decrease growth and/or affect abnormal characteristics of cancerous or displastic colon cells).

ABFR L'invention concerne la decouverte de polynucleotides representant des genes qui s'expriment de maniere differente dans le cancer du colon, un polype adenomateux par exemple, un carcinome colo-rectal, une tumeur du colon a fort potentiel metastatique et un cancer du colon metastatique. L'invention concerne egalement des procedes d'identification de cellules affectees par de telles maladies du colon, grace a la detection d'un produit genetique code par ces genes exprimes de maniere differente, ainsi qu'un procede de modulation de l'expression de ces produits genetiques pour appliquer une therapie (reduire la croissance et/ou affecter les caracteristiques anormales de cellules de colon dysplasique ou cancereux, par exemple).

L28 ANSWER 23 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001090327 PCTFULL ED 20020826
TITLE (ENGLISH): 21910, A MEMBRANE-ASSOCIATED GUANYLATE KINASE AND USES THEREOF
TITLE (FRENCH): 21910, UNE NOUVELLE GUANYLATE KINASE ASSOCIEE A LA MEMBRANE HUMAINE ET UTILISATIONS ASSOCIEES
INVENTOR(S): KAPELLER-LIBERMANN, Rosana; HUNTER, John, Joseph
PATENT ASSIGNEE(S): MILLENNIUM PHARMACEUTICALS, INC.; KAPELLER-LIBERMANN, Rosana; HUNTER, John, Joseph
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001090327	A2	20011129

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW
MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US16565 A 20010521
PRIORITY INFO.: US 2000-60/205,447 20000519
US 2000-09/711,216 20001109

ABEN The invention provides isolated nucleic acid molecules, designated MAGK nucleic acid molecules, which encode novel guanylate kinase related molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing MAGK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a MAGK gene has been introduced or disrupted. The invention still further provides isolated MAGK proteins, antigenic peptides and anti-MAGK antibodies. Treatment and diagnostic

methods for cellular growth or proliferation diseases or disorders, e.g, cancer, including, but not limited to colon cancer and lung cancer, utilizing compositions of the invention, are also provided.

ABFR L'invention concerne des molecules d'acide nucleiques isolees, appelees molecules d'acide nucleique MAGK, codant pour des nouvelles molecules liees a une guanylate kinase. L'invention concerne egalement des molecules d'acide nucleique antisens, des vecteurs d'expression de recombinaison contenant les molecules d'acide nucleique MAGK, des cellules hotes dans lesquelles les vecteurs d'expression ont ete introduits, et des animaux transgeniques non humains dans lesquels un gene MAGK a ete introduit ou interrompu. L'invention concerne egalement des proteines MAGK isolees, des proteines hybrides, des peptides antigenes et des anticorps anti-MAGK. L'invention concerne egalement des methodes therapeutiques et diagnostiques pour des maladies ou des troubles proliferants ou a croissance cellulaire, tels que le cancer, y compris notamment, mais pas exclusivement, le cancer du colon et le cancer du poumon, a l'aide des compositions decrites dans la presente invention.

L28 ANSWER 24 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001072781 PCTFULL ED 20020822

TITLE (ENGLISH): HUMAN GENES AND EXPRESSION PRODUCTS

TITLE (FRENCH): GENES HUMAINS ET PRODUITS D'EXPRESSION GENIQUE XVI

INVENTOR(S): WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; HE, Zhijun; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David A.; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, Lee, William; STACHE-CRAIN, Birgit

PATENT ASSIGNEE(S): CHIRON CORPORATION; HYSEQ INC.; WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; HE, Zhijun; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David A.; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, Lee, William; STACHE-CRAIN, Birgit

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001072781	A2	20011004
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US9952	A	20010327
PRIORITY INFO.:	US 2000-60/192,583		20000328

ABEN This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variant thereof, to genes corresponding to theses polynucleotides and to proteins expressed by the genes. This invention also relates to diagnostic and therapeutic agents employing such novel polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

ABFR L'invention concerne de nouveaux polynucleotides humains et des variants de ces derniers, leurs polypeptides codees et des variants de ces

derniers, des genes correspondant a ces polynucleotides et a des proteines exprimees par ces genes. L'invention concerne egalement des agents diagnostiques et therapeutiques utilisant ces nouveaux polynucleotides, leurs genes ou produits geniques correspondants, par exemple ces genes et proteines, y compris des sondes, des constructions anti-sens et des anticorps.

L28 ANSWER 25 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001066753 PCTFULL ED 20020822
TITLE (ENGLISH): HUMAN GENES AND GENE EXPRESSION PRODUCTS
TITLE (FRENCH): NOUVEAUX GENES HUMAINS ET LEURS PRODUITS D'EXPRESSION
INVENTOR(S): WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, William, Lee; STACHE-CRAIN, Birgit
PATENT ASSIGNEE(S): CHIRON CORPORATION; HYSEQ INC.; WILLIAMS, Lewis, T.; ESCOBEDO, Jaime; INNIS, Michael, A.; GARCIA, Pablo, Dominguez; SUDDUTH-KLINGER, Julie; REINHARD, Christoph; RANDAZZO, Filippo; KENNEDY, Giulia, C.; POT, David; KASSAM, Altaf; LAMSON, George; DRMANAC, Radoje; CRKVENJAKOV, Radomir; DICKSON, Mark; DRMANAC, Snezana; LABAT, Ivan; LESHKOWITZ, Dena; KITA, David; GARCIA, Veronica; JONES, William, Lee; STACHE-CRAIN, Birgit
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001066753	A2	20010913

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US7787 A 20010309
PRIORITY INFO.: US 2000-60/188,609 20000309

ABEN This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

ABFR L'invention porte sur de nouveaux polynucleotides humains et leurs variantes, sur les polypeptides codes par eux et leurs variantes, sur les genes correspondant a ces polynucleotides, et sur des proteines exprimees par ces genes. L'invention porte egalement sur des agents diagnostiques et therapeutiques utilisant lesdits nouveaux polynucleotides humains et les genes et produits geniques correspondants, ces genes et proteines comportant des sondes, des produits d'assemblage et des anticorps.

L28 ANSWER 26 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001055322 PCTFULL ED 20020827
TITLE (ENGLISH): NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TITLE (FRENCH): ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS
INVENTOR(S): ROSEN, Craig, A.; BARASH, Steven, C.; RUBEN, Steven, M.
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; ROSEN, Craig, A.; BARASH,

Steven, C.; RUBEN, Steven, M.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001055322	A2	20010802

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2001-US1341	A	20010117
PRIORITY INFO.:	US 2000-60/179,065		20000131
	US 2000-60/180,628		20000204
	US 2000-60/184,664		20000224
	US 2000-60/186,350		20000302
	US 2000-60/189,874		20000316
	US 2000-60/190,076		20000317
	US 2000-60/198,123		20000418
	US 2000-60/205,515		20000519
	US 2000-60/209,467		20000607
	US 2000-60/214,886		20000628
	US 2000-60/215,135		20000630
	US 2000-60/216,647		20000707
	US 2000-60/216,880		20000707
	US 2000-60/217,487		20000711
	US 2000-60/217,496		20000711
	US 2000-60/218,290		20000714
	US 2000-60/220,963		20000726
	US 2000-60/220,964		20000726
	US 2000-60/225,757		20000814
	US 2000-60/225,270		20000814
	US 2000-60/225,447		20000814
	US 2000-60/225,267		20000814
	US 2000-60/225,758		20000814
	US 2000-60/225,268		20000814
	US 2000-60/224,518		20000814
	US 2000-60/224,519		20000814
	US 2000-60/225,759		20000814
	US 2000-60/225,213		20000814
	US 2000-60/225,266		20000814
	US 2000-60/225,214		20000814
	US 2000-60/226,279		20000818
	US 2000-60/226,868		20000822
	US 2000-60/227,182		20000822
	US 2000-60/226,681		20000822
	US 2000-60/227,009		20000823
	US 2000-60/228,924		20000830
	US 2000-60/229,344		20000901
	US 2000-60/229,343		20000901
	US 2000-60/229,287		20000901
	US 2000-60/229,345		20000901
	US 2000-60/229,513		20000905
	US 2000-60/229,509		20000905
	US 2000-60/230,438		20000906
	US 2000-60/230,437		20000906
	US 2000-60/231,413		20000908
	US 2000-60/232,080		20000908
	US 2000-60/231,414		20000908
	US 2000-60/231,244		20000908
	US 2000-60/232,081		20000908

US 2000-60/231,242	20000908
US 2000-60/231,243	20000908
US 2000-60/231,968	20000912
US 2000-60/232,401	20000914
US 2000-60/232,399	20000914
US 2000-60/232,400	20000914
US 2000-60/232,397	20000914
US 2000-60/233,063	20000914
US 2000-60/233,064	20000914
US 2000-60/233,065	20000914
US 2000-60/232,398	20000914
US 2000-60/234,223	20000921
US 2000-60/234,274	20000921
US 2000-60/234,997	20000925
US 2000-60/234,998	20000925
US 2000-60/235,484	20000926
US 2000-60/235,834	20000927
US 2000-60/235,836	20000927
US 2000-60/236,369	20000929
US 2000-60/236,327	20000929
US 2000-60/236,370	20000929
US 2000-60/236,368	20000929
US 2000-60/236,367	20000929
US 2000-60/237,039	20001002
US 2000-60/237,038	20001002
US 2000-60/237,040	20001002
US 2000-60/237,037	20001002
US 2000-60/236,802	20001002
US 2000-60/239,937	20001013
US 2000-60/239,935	20001013
US 2000-60/241,785	20001020
US 2000-60/241,809	20001020
US 2000-60/240,960	20001020
US 2000-60/241,787	20001020
US 2000-60/241,808	20001020
US 2000-60/241,221	20001020
US 2000-60/241,786	20001020
US 2000-60/241,826	20001020
US 2000-60/244,617	20001101
US 2000-60/246,474	20001108
US 2000-60/246,532	20001108
US 2000-60/246,476	20001108
US 2000-60/246,526	20001108
US 2000-60/246,475	20001108
US 2000-60/246,525	20001108
US 2000-60/246,528	20001108
US 2000-60/246,527	20001108
US 2000-60/246,477	20001108
US 2000-60/246,611	20001108
US 2000-60/246,610	20001108
US 2000-60/246,613	20001108
US 2000-60/246,609	20001108
US 2000-60/246,478	20001108
US 2000-60/246,524	20001108
US 2000-60/246,523	20001108
US 2000-60/249,299	20001117
US 2000-60/249,210	20001117
US 2000-60/249,216	20001117
US 2000-60/249,217	20001117
US 2000-60/249,211	20001117
US 2000-60/249,215	20001117
US 2000-60/249,218	20001117
US 2000-60/249,208	20001117
US 2000-60/249,213	20001117

US 2000-60/249,212	20001117
US 2000-60/249,207	20001117
US 2000-60/249,245	20001117
US 2000-60/249,244	20001117
US 2000-60/249,297	20001117
US 2000-60/249,214	20001117
US 2000-60/249,264	20001117
US 2000-60/249,209	20001117
US 2000-60/249,300	20001117
US 2000-60/249,265	20001117
US 2000-60/250,391	20001201
US 2000-60/250,160	20001201
US 2000-60/256,719	20001205
US 2000-60/251,030	20001205
US 2000-60/251,988	20001205
US 2000-60/251,479	20001206
US 2000-60/251,869	20001208
US 2000-60/251,856	20001208
US 2000-60/251,868	20001208
US 2000-60/251,990	20001208
US 2000-60/251,989	20001208
US 2000-60/254,097	20001211
US 2001-60/259,678	20010105

ABEN The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

ABFR La presente invention concerne de nouvelles proteines. Plus specifiquement, l'invention concerne des molecules d'acide nucleique isolees, codant pour de nouveaux polypeptides. Cette invention concerne egalement : de nouveaux polypeptides et anticorps qui se lient a ces polypeptides ; des vecteurs, des cellules hotes, et des procedes de recombinaison et de synthese permettant de produire des polynucleotides et/ou polypeptides humains, et des anticorps ; des procedes diagnostiques et therapeutiques utiles pour le diagnostic, le traitement, la prevention et/ou la prevision de troubles lies a ces nouveaux polypeptides ; des procedes de criblage permettant d'identifier des agonistes et des antagonistes de polynucleotides et polypeptides de l'invention ; des procedes et/ou des compositions permettant d'inhiber ou d'augmenter la production et la fonctionnalite de polypeptides de la presente invention.

L28 ANSWER 27 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001049879 PCTFULL ED 20020827
TITLE (ENGLISH): METHODS FOR COMPARING GENE EXPRESSION LEVELS OR PATTERNS IN NORMAL OR TUMOR CELLS
TITLE (FRENCH): EXPRESSION GENIQUE ET ETATS BIOLOGIQUES
INVENTOR(S): ORNTOFT, Torben, F; THYKJAER, Thomas; DEMTROeDER, Karin; FREDERIKSEN, Casper, Moller
PATENT ASSIGNEE(S): AROS APPLIED BIOTECHNOLOGY APS; ORNTOFT, Torben, F; THYKJAER, Thomas; DEMTROeDER, Karin; FREDERIKSEN, Casper, Moller
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

	WO 2001049879 A2 20010712
DESIGNATED STATES	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:	WO 2000-DK744 A 20001229
PRIORITY INFO.:	DK 1999-PA 1999 01867 19991229

ABEN The invention concerns a method of determining the presence or absence of a biological condition in humans, in particular of colon cancer, and of determining the stage of a condition in human tissue by determining an expression pattern of a cell sample. Further, the invention relates to a method of determining the presence or absence of a biological condition in human tissue, and of determining the stage of a biological condition in human tissue, and also for reducing biological abnormalities of a cell suffering from the biological condition. A method for producing antibodies against an expression product of a cell from the tissue is also described. The invention also discloses a pharmaceutical composition for the treatment of a biological condition comprising at least one antibody, and a vaccine for the prophylaxis or treatment of a biological condition. Further the invention describes the use of a method for producing an assay for diagnosing a biological condition in human tissue, the use of a peptide or a gene or a probe for the preparation of a pharmaceutical composition for the treatment of a biological condition in human tissue, and an assay for determining the presence or absence of biological condition in human tissue and for determining an expression pattern of a cell.

ABFR L'invention concerne un procede permettant d'une part, de determiner la presence ou l'absence d'un etat biologique chez l'homme, notamment le cancer du colon, et d'autre part, de determiner le stade d'avancement d'un etat au niveau des tissus humains par la determination du schema d'expression d'un echantillon de cellules. En outre, l'invention concerne un procede permettant de determiner la presence ou l'absence d'un etat biologique au niveau de tissus humains, de determiner le stade d'avancement d'un etat biologique au niveau de tissus humains, et de reduire egalement les anomalies biologiques d'une cellule touchee par cet etat biologique. L'invention concerne egalement un procede de production d'anticorps diriges contre le produit d'expression d'une cellule tiree de ces tissus. L'invention concerne aussi une composition pharmaceutique, destinee au traitement d'un etat biologique, qui contient au moins un anticorps, ainsi qu'un vaccin prophylactique ou therapeutique contre un etat biologique. L'invention concerne enfin l'utilisation d'un procede de production d'un dosage permettant de diagnostiquer un etat biologique dans des tissus humains, l'utilisation d'un peptide, d'un gene ou d'une sonde pour la preparation d'une composition pharmaceutique destinee au traitement d'un etat biologique au niveau de tissus humains, et un dosage servant a determiner la presence ou l'absence d'un etat biologique au niveau de tissus humains et a determiner le schema d'expression d'une cellule.

L28 ANSWER 28 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER:	2001036638 PCTFULL ED 20020820
TITLE (ENGLISH):	NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
TITLE (FRENCH):	NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES CODANT POUR CES POLYPEPTIDES
INVENTOR(S):	SHIMKETS, Richard, A.; LICHENSTEIN, Henri; VERNET, Corine; FERNANDES, Elma
PATENT ASSIGNEE(S):	CURAGEN CORPORATION; SHIMKETS, Richard, A.; LICHENSTEIN, Henri; VERNET, Corine; FERNANDES, Elma
DOCUMENT TYPE:	Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001036638	A2	20010525

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US31543 A 20001117

PRIORITY INFO.: US 1999-60/166,336 19991119
US 1999-60/167,785 19991129
US 2000-60/187,844 20000308
US 2000-60/187,844 20001116

ABEN The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

ABFR

L28 ANSWER 29 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2001062891 PCTFULL ED 20020822

TITLE (ENGLISH): 207 HUMAN SECRETED PROTEINS

TITLE (FRENCH): 207 PROTEINES HUMAINES SECRETEES

INVENTOR(S): NI, Jian; EBNER, Reinhard; LAFLEUR, David, W.; MOORE, Paul, A.; OLSEN, Henrik, S.; ROSEN, Craig, A.; RUBEN, Steven, M.; SOPPET, Daniel, R.; YOUNG, Paul, E.; SHI, Yanggu; FLORENCE, Kimberly, A.; WEI, Ying-Fei; FLORENCE, Charles; HU, Jing-Shan; LI, Yi; KYAW, Hla; FISCHER, Carrie, L.; FERRIE, Ann, M.; FAN, Ping; FENG, Ping; ENDRESS, Gregory, A.; DILLON, Patrick, J.; CARTER, Kennith, C.; BREWER, Laurie, A.; YU, Guo-Liang; ZENG, Zhizhen; GREENE, John, M.

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; NI, Jian; EBNER, Reinhard; LAFLEUR, David, W.; MOORE, Paul, A.; OLSEN, Henrik, S.; ROSEN, Craig, A.; RUBEN, Steven, M.; SOPPET, Daniel, R.; YOUNG, Paul, E.; SHI, Yanggu; FLORENCE, Kimberly, A.; WEI, Ying-Fei; FLORENCE, Charles; HU, Jing-Shan; LI, Yi; KYAW, Hla; FISCHER, Carrie, L.; FERRIE, Ann, M.; FAN, Ping; FENG, Ping; ENDRESS, Gregory, A.; DILLON, Patrick, J.; CARTER, Kennith, C.; BREWER, Laurie, A.; YU, Guo-Liang; ZENG, Zhizhen; GREENE, John, M.

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2001062891	A2	20010830

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2001-US5614 A 20010221

PRIORITY INFO.: US 2000-60/184,836 20000224
US 2000-60/193,170 20000329

ABEN The present invention relates to the novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

ABFR La presente invention concerne de nouvelles proteines humaines secretees ainsi que des acides nucleiques isoles contenant les regions codantes des genes codant ces proteines. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps ainsi que des methodes de recombinaison permettant la production de proteines humaines secretees. L'invention concerne egalement des methodes de diagnostic et therapeutiques utiles pour diagnostiquer et traiter des maladies, des troubles et/ou des etats lies a ces nouvelles proteines humaines secretees.

L28 ANSWER 30 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001046255 PCTFULL ED 20020827
TITLE (ENGLISH): NK CELL RECEPTOR POLYNUCLEOTIDES, POLYPEPTIDES, AND ANTIBODIES
TITLE (FRENCH): POLYNUCLEOTIDES, POLYPEPTIDES, ET ANTICORPS DU RECEPTEUR DE CELLULES NK
INVENTOR(S): RUBEN, Steven, M.; SHI, Yang-gu
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; RUBEN, Steven, M.; SHI, Yang-gu
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001046255	A1	20010628

DESIGNATED STATES AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2000-US34770 A 20001221
PRIORITY INFO.: US 1999-60/171,506 19991222

ABEN The present invention relates to novel human NKCR polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human NKCR polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human NKCR polypeptides.

ABFR L'invention concerne de nouveaux polypeptides NKCR humains et des acides nucleiques isoles renfermant les regions codantes des genes codant pour ces polypeptides. L'invention concerne egalement des vecteurs, des cellules hotes, des anticorps et des procedes de recombinaison destines a la production de polypeptides NKCR humains. L'invention concerne des methodes diagnostiques et therapeutiques utiles pour diagnostiquer et traiter des maladies liees a ces nouveaux polypeptides NKCR humains.

L28 ANSWER 31 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001034629 PCTFULL ED 20020820
TITLE (ENGLISH): 21 HUMAN SECRETED PROTEINS
TITLE (FRENCH): 21 PROTEINES HUMAINES SECRETEES
INVENTOR(S): RUBEN, Steven, M.; KOMATSOULIS, George, A.; WEI, Ping; FISCELLA, Michele; BAKER, Kevin, P.

PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.; RUBEN, Steven, M.; KOMATSOULIS, George, A.; WEI, Ping; FISCELLA, Michele; BAKER, Kevin, P.
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001034629	A1	20010517

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-US30654	A	20001108
PRIORITY INFO.:	US 1999-60/164,835		19991112
	US 2000-60/221,142		20000727

ABEN The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.
ABFR

L28 ANSWER 32 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2001025466 PCTFULL ED 20020820
TITLE (ENGLISH): PRODUCER CELL FOR THE PRODUCTION OF RETROVIRAL VECTORS
TITLE (FRENCH): CELLULE DE PRODUCTION
INVENTOR(S): SLINGSBY, Jason; KINGSMAN, Susan, Mary; ROHLL, Jonathan; SLADE, Andrew
PATENT ASSIGNEE(S): OXFORD BIOMEDICA (UK) LIMITED; SLINGSBY, Jason; KINGSMAN, Susan, Mary; ROHLL, Jonathan; SLADE, Andrew
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2001025466	A1	20010412

DESIGNATED STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-GB3837	A	20001005
PRIORITY INFO.:	GB 1999-9923558.2		19991005

ABEN A method is provided for modifying a producer cell which producer cell comprises integrated into its genome a provirus which provirus comprises one or more recombinase recognition sequences within or upstream of its 3' LTR, the method comprising: introducing into the cell a construct comprising a 5' recombinase recognition sequence, an LTR and a 3' recombinase recognition sequence in that order, in the presence of a recombinase which is capable of acting on the recombinase recognition site(s) such that the nucleotide sequence between the 5' and 3' recombinase recognition sequences in the construct is introduced into the provirus.
ABFR

L28 ANSWER 33 OF 61 USPATFULL

ACCESSION NUMBER: 2001:173353 USPATFULL
TITLE: Methods of use of a novel lysyl oxidase-related protein
INVENTOR(S): Khodadoust, Mehran M., Brookline, MA, United States
MacBeth, Kyle J., Boston, MA, United States
PATENT ASSIGNEE(S): Millennium Pharmaceuticals Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6300092	B1	20011009
APPLICATION INFO.:	US 1999-448076		19991123 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-276400, filed on 25 Mar 1999, now patented, Pat. No. US 6140056, issued on 31 Oct 2000

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-117580P	19990127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
LEGAL REPRESENTATIVE: Lahive & Cockfield, LLP, Mandragouras, Amy E., Milasincic, Debra J.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 4218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel Lor-2 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Lor-2 proteins, the invention further provides isolated Lor-2 fusion proteins, antigenic peptides and anti-Lor-2 antibodies. The invention also provides Lor-2 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Lor-2 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 34 OF 61 USPATFULL
ACCESSION NUMBER: 2001:107613 USPATFULL
TITLE: Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
INVENTOR(S): Littman, Dan R., New York, NY, United States
Deng, Hongkui, Worcester, MA, United States
Ellmeier, Wilfried, New York, NY, United States
Landau, Nathaniel R., New York, NY, United States
Liu, Rong, New York, NY, United States
PATENT ASSIGNEE(S): The Aaron Diamond Aids Research Center, New York, NY, United States (U.S. corporation)
New York University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258527	B1	20010710
APPLICATION INFO.:	US 1997-861105		19970521 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-858660, filed on 19 May 1997, now abandoned

	NUMBER	DATE

PRIORITY INFORMATION:	US 1996-17157P	19960520 (60)
	US 1996-20043P	19960619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Budens, Robert D.	
LEGAL REPRESENTATIVE:	Klauber & Jackson	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1,8,13,17	
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	2295	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 35 OF 61 USPATFULL

ACCESSION NUMBER:	2001:71355 USPATFULL		
TITLE:	Methods to inhibit replication of infective virus		
INVENTOR(S):	Dropulic, Boro, Ellicott City, MD, United States Pitha, Paula M., Baltimore, MD, United States		
PATENT ASSIGNEE(S):	The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6232120	B1	20010515
APPLICATION INFO.:	US 1999-251283		19990216 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-917625, filed on 22 Aug 1997, now patented, Pat. No. US 5888767 Division of Ser. No. US 1996-758598, filed on 27 Nov 1996, now patented, Pat. No. US 5885806		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1995-32800P	19951128 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
ASSISTANT EXAMINER:	Larson, Thomas G		
LEGAL REPRESENTATIVE:	Morrison & Foerster		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	2627		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy

and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 36 OF 61 USPATFULL

ACCESSION NUMBER:	2001:63423 USPATFULL
TITLE:	Assays for screening for inhibitors of HIV
INVENTOR(S):	Karn, Jonathan, Cambridge, United Kingdom Zemmel, Rodney Warren, London, United Kingdom Butler, Peter Jonathan Gasking, Cambridge, United Kingdom Craig, Roger K., Cheshire, United Kingdom Irvine, Alistair Simpson, Derbyshire, United Kingdom
PATENT ASSIGNEE(S):	Ribotargets, Ltd., Cambridge, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225045	B1	20010501
APPLICATION INFO.:	US 1997-839624		19970415 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17268P	19960513 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Myers, Carla J.
LEGAL REPRESENTATIVE:	Palmer & Dodge, LLP, Williams, Kathleen Madden
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT:	2808

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to an isolated nucleic acid comprising two operatively linked binding sites for HIV Rev protein, the sites comprising a nucleation motif and an oligomerization motif, wherein the nucleic acid binds Rev protein monomers with a higher degree of co-operativity than wild-type RRE.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 37 OF 61 USPATFULL

ACCESSION NUMBER:	2001:43984 USPATFULL
TITLE:	Conditionally replicating viral vectors and their use
INVENTOR(S):	Dropulic, Boro, Ellicott City, MD, United States Pitha, Paula M., Baltimore, MD, United States
PATENT ASSIGNEE(S):	The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207426	B1	20010327
APPLICATION INFO.:	US 1999-251084		19990216 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-917625, filed on 22 Aug 1997, now patented, Pat. No. US 5888767 Division of Ser. No. US 1996-758598, filed on 27 Nov 1996, now patented, Pat. No. US 5885806		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-32800P	19951128 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Schwartzman, Robert A.

ASSISTANT EXAMINER: Larson, Thomas G.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2599
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 38 OF 61 USPATFULL
ACCESSION NUMBER: 2001:1641 USPATFULL
TITLE: Genetic antiviral agents and methods for their use
INVENTOR(S): Dropulic, Boro, Ellicott City, MD, United States
Pitha, Paula M., Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6168953	B1	20010102
APPLICATION INFO.:	US 1999-312322		19990514 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-251283, filed on 16 Feb 1999 Division of Ser. No. US 1997-917625, filed on 22 Aug 1997, now patented, Pat. No. US 5888767 Division of Ser. No. US 1996-758598, filed on 27 Nov 1996, now patented, Pat. No. US 5885806

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-32800P	19951128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartzman, Robert A.
ASSISTANT EXAMINER: Larson, Thomas G.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2603
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 39 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000052186 PCTFULL ED 20020515
TITLE (ENGLISH): MEANS AND METHODS FOR FIBROBLAST-LIKE OR MACROPHAGE-LIKE CELL TRANSDUCTION
TITLE (FRENCH): TRANSDUCTION DE CELLULES RESSEMBLANT A DES FIBROBLASTES OU A DES MACROPHAGES ET MOYENS A CET EFFET
INVENTOR(S): VOGELS, Ronald; SCHOUTEN, Govert, Johan; BOUT, Abraham
PATENT ASSIGNEE(S): INTROGENE B.V.; VOGELS, Ronald; SCHOUTEN, Govert, Johan; BOUT, Abraham
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000052186	A1	20000908

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2000-NL133 A	20000303
PRIORITY INFO.:	EP 1999-99200624.7	19990304

ABEN The invention provides a nucleic acid delivery vehicle with or having been provided with at least a tissue tropism for fibroblast-like or macrophage-like cells, preferably synoviocytes. In one aspect said nucleic acid delivery vehicle is a virus capsid or a functional part, derivative and/or analogue thereof. Preferably said virus capsid is an adenovirus capsid. Preferably said adenovirus is a subgroup B adenovirus, preferably adenovirus 16. Preferably said tissue tropism is provided by at least a tissue tropism determining part of an adenovirus fiber protein or a functional derivative and/or analogue thereof. The invention further presents methods for the treatment of diseases, preferably joint related diseases.

ABFR La presente invention concerne un vehicule d'apport d'acide nucleique dote, spontanement ou non, d'au moins un tropisme pour des cellules ressemblant aux fibroblastes ou aux macrophages, de preference des cellules synoviales. Pour un aspect de l'invention, ce vehicule d'apport d'acide nucleique est une capside virale, l'une de ses parties fonctionnelles, l'un de ses derives et/ou analogues. De preference, cette capside virale est une capside adenovirale. De preference, ledit adenovirus est un adenovirus du sous-groupe B, de preference l'adenovirus 16. Le tropisme tissulaire est confere par au moins une partie determinant le tropisme tissulaire d'une proteine adenovirale fibrale, ou de l'un de ses derives et/ou analogues fonctionnels. L'invention porte enfin sur des procedures de traitement d'affections, de preference de nature articulaire.

L28 ANSWER 40 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000044910 PCTFULL ED 20020515
TITLE (ENGLISH): METHODS OF USE OF A NOVEL LYSYL OXIDASE-RELATED PROTEIN

TITLE (FRENCH): METHODES D'UTILISATION D'UNE NOUVELLE PROTEINE ASSOCIEE A LA LYSYLE OXYDASE
INVENTOR(S): KHODADOUST, Mehran, M.; MACBETH, Kyle, J.
PATENT ASSIGNEE(S): MILLENNIUM PHARMACEUTICALS, INC.; KHODADOUST, Mehran, M.; MACBETH, Kyle, J.
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000044910	A1	20000803
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US2125	A	20000127
PRIORITY INFO.:	US 1999-60/117,580		19990127
	US 1999-09/276,400		19990325
	US 1999-09/448,076		19991123

ABEN Novel Lor-2 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Lor-2 proteins, the invention further provides isolated Lor-2 fusion proteins, antigenic peptides and anti-Lor-2 antibodies. The invention also provides Lor-2 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Lor-2 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

ABFR L'invention se rapporte a de nouveaux polypeptides de Lor-2, a de nouvelles proteines et molecules d'acides nucleiques associees. En plus des proteines de Lor-2 entieres, isolees, l'invention concerne des proteines de fusion de Lor-2, des peptides antigeniques et des anticorps anti-Lor-2. L'invention se rapporte egalement a des molecules d'acides nucleiques de Lor-2, a des vecteurs d'expression recombinants contenant une telle molecule d'acide nucleique, a des cellules hotes dans lesquelles les vecteurs d'expression ont ete introduits et a des animaux transgeniques non humains dans lesquels un gene Lor-2 a ete introduit ou disloque. Des methodes diagnostiques, analytiques et therapeutiques utilisant des compositions de cette invention sont egalement decrites.

L28 ANSWER 41 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000044406 PCTFULL ED 20020515
TITLE (ENGLISH): DNA VACCINES AGAINST HANTAVIRUS INFECTIONS
TITLE (FRENCH): VACCINS ADN DIRIGES CONTRE LES INFECTIONS A HANTAVIRUS
INVENTOR(S): SCHMALJOHN, Connie, S.; HOOPER, J., W.
PATENT ASSIGNEE(S): U.S. MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES; SCHMALJOHN, Connie, S.; HOOPER, J., W.
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE

WO 2000044406 A2 20000803

DESIGNATED STATES AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US1999 A 20000127

PRIORITY INFO.: US 1999-60/117,680 19990129

ABEN Seoul virus (SEOV) is one of four known hantaviruses causing hemorrhagic fever with renal syndrome (HFRS). Candidate naked DNA vaccines for HFRS were constructed by subcloning cDNA representing the medium (M) (encoding the G1 and G2 glycoproteins) or small (S) (encoding the nucleocapside protein) genome segment of SEOV into the DNA expression vector pWRG7077. We vaccinated BALB/c mice with three doses of the M or S DNA vaccine at 4-week intervals by either gene gun inoculation of the epidermis, or needle inoculation into the gastrocnemius muscle. Both routes of vaccination resulted in antibody responses as measured by ELISA; however, gene gun inoculation elicited a higher frequency of seroconversion, and higher levels of antibodies in individual mice. We vaccinated Syrian hamsters with the M or S construct using the gene gun and found hantavirus-specific antibodies in 5/5 and 4/5 hamsters, respectively. Animals vaccinated with the M construct developed a neutralizing antibody response which was greatly enhanced in the presence of guinea pig complement. Immunized hamsters were challenged with SEOV and, after 28 days, were monitored for evidence of infection. Hamsters vaccinated with M were protected from infection, but hamsters vaccinated with S were not protected.

ABFR Le virus Seoul (SEOV) est l'un des quatre hantavirus connus provoquant la fievre hemorragique avec syndrome renal (HFRS). On a donc mis au point des vaccins a ADN nu par sous-clonage de l'ADNc representant le segment moyen (M) (codant pour les glycoproteines G1 et G2) ou le petit (S) segment (codant pour la nucleocapside) du genome du virus Seoul de facon a obtenir un vecteur pWRG7077 d'expression a base d'ADN. Nous avons vaccine des souris BALB/c avec trois doses de vaccin a ADN M ou S a des intervalles de 4 semaines soit par inoculation intra-epidermique au pistolet a genes, soit par inoculation a l'aiguille dans le muscle gastrocnemien. Les deux voies de vaccination ont provoque les reponses anticorps telles que mesurees conformement a la technique immuno-enzymologique (ELISA); cependant, l'inoculation au pistolet a genes a declenche une seroconversion bien plus frequente, ainsi que des niveaux d'anticorps plus eleves chez chacune des souris. Nous avons vaccine des hamsters syriens avec la construction M ou S a l'aide du pistolet a genes, et nous avons decouvert des anticorps specifiques des hantavirus, respectivement chez 5/5 et 4/5 hamsters. Les animaux vaccines avec la construction M ont presente une reponse anticorps neutralisante fortement

activee en presence du complement du cobaye. On a effectue une vaccination de rappel a SEOV chez les hamsters immunises puis, 28 jours plus tard, on les a examines de maniere a detecter toute trace d'infection. Les hamsters vaccines avec M ont ete proteges contre l'infection, contrairement aux hamsters vaccines avec S.

L28 ANSWER 42 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2000028079 PCTFULL ED 20020515

TITLE (ENGLISH): GENETIC VARIATION ASSOCIATED WITH APLASTIC ANEMIA, AND DIAGNOSIS AND THERAPY BASED THEREON

TITLE (FRENCH): VARIATION GENETIQUE ASSOCIEE A L'ANEMIE APLASIQUE, ET APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES BASEES SUR CETTE VARIATION

INVENTOR(S): DAHL, Niklas;; GUSTAVSSON, Peter;; DRAPTCHINSKAIA, Natalia

PATENT ASSIGNEE(S): EURONA MEDICAL AB; DAHL, Niklas;; GUSTAVSSON, Peter;; DRAPTCHINSKAIA, Natalia

LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000028079	A2	20000518

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-IB1794 A 19991108

PRIORITY INFO.: US 1998-60/107,613 19981109

US 1999-60/118,664 19990126

ABEN The present invention relates to identification of a gene that is inactivated in an aplastic anemia. In particular, the invention concerns mutations that disrupt a ribosomal protein (RP), preferably RP S19, in Diamond-Blackfan Anemia (DBA). Recombinant nucleic acids encoding mutant forms of DBA, oligonucleotides specific for such mutations, and diagnostic and therapeutic applications related to these discoveries, are also contemplated.

ABFR La presente invention concerne l'identification d'un gene qui est inactive dans le cas d'une anemie aplasique. L'invention concerne, en particulier, des mutations qui dereglent une proteine ribosomale, de preference RP S19, dans le cas de l'anemie de Blackfan-Diamond. L'invention concerne egalement des acides nucleiques de recombinaison codant des formes mutantes de l'anemie de Blackfan-Diamond, des oligonucleotides specifiques de ces mutations, ainsi que les applications diagnostiques et therapeutiques associees a ces decouvertes.

L28 ANSWER 43 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2000024771 PCTFULL ED 20020515

TITLE (ENGLISH): NUCLEIC ACIDS ENCODING OSTEOPROTEGERIN-LIKE PROTEINS AND METHODS OF USING SAME

TITLE (FRENCH): ACIDES NUCLEIQUES CODANT POUR DES PROTEINES SEMBLABLES A L'OSTEOPROTEGERINE ET METHODES D'UTILISATION ASSOCIEES

INVENTOR(S): SHIMKETS, Richard, A.; YANG, Meijia; LICHENSTEIN, Henri; MCDONALD, William, F.
PATENT ASSIGNEE(S): CURAGEN CORPORATION; SHIMKETS, Richard, A.; YANG, Meijia; LICHENSTEIN, Henri; MCDONALD, William, F.
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000024771	A2	20000504

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 1999-US24913	A	19991022
PRIORITY INFO.:	US 1998-60/105,481		19981023
	US 1999-60/156,993		19991001
	US 1999-09/422,680		19991021

ABEN Disclosed are osteoprotegerin-like polypeptides, nucleic acids encoding osteoprotegerin-like polypeptides, and methods of using these molecules. The osteoprotegerin-like polypeptides sequence homology to osteoprotegerin and tumor necrosis factor receptor molecules.

ABFR L'invention se rapporte a des polypeptides semblables a l'osteoprotegerine, a des acides nucleiques codant pour ces polypeptides semblables a l'osteoprotegerine, et a des methodes d'utilisation de ces molecules. Elle se rapporte egalement a l'homologie des sequences des polypeptides semblables a l'osteoprotegerine avec les molecules d'osteoprotegerine et les molecules receptrices du facteur de necrose des tumeurs.

L28 ANSWER 44 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000023588 PCTFULL ED 20020515
TITLE (ENGLISH): G-PROTEIN COUPLED RECEPTORS
TITLE (FRENCH): RECEPTEURS COUPLES A LA PROTEINE G
INVENTOR(S): GLUCKSMANN, Maria, Alexandra; WEICH, Nadine, S.
PATENT ASSIGNEE(S): MILLENNIUM PHARMACEUTICALS, INC.; GLUCKSMANN, Maria, Alexandra; WEICH, Nadine, S.
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000023588	A2	20000427

DESIGNATED STATES: AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 1999-US24368	A	19991018
PRIORITY INFO.:	US 1998-09/173,869		19981016
	US 1999-09/173,869		19991018

ABEN The present invention relates to newly identified receptors belonging to the superfamily of

G-protein-coupled receptors. The invention also relates to polynucleotides encoding the receptors. The invention further relates to methods using the receptor polypeptides and polynucleotides as a target for diagnosis and treatment in receptor-mediated disorders. The invention further relates to drug-screening methods using the receptor polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the receptor polypeptides and polynucleotides. The invention further relates to procedures for producing the receptor polypeptides and polynucleotides.

ABFR La presente invention concerne des recepteurs nouvellement identifies appartenant a la superfamille des recepteurs couples a une proteine G. Cette invention concerne egalement des polynucleotides codant ces recepteurs. Par ailleurs, cette invention concerne des procedes utilisant ces polypeptides et polynucleotides recepteurs comme cible pour le diagnostic et le traitement de troubles induits par les recepteurs. De meme, cette invention concerne des procedes de criblage de medicaments utilisant ces polypeptides et polynucleotides recepteurs pour identifier les agonistes et les antagonistes permettant le diagnostic et le traitement, et concerne aussi les agonistes et les antagonistes bases sur les polynucleotides et polypeptides recepteurs. Enfin, cette invention concerne des methodes de production de ces polypeptides et polynucleotides recepteurs.

L28 ANSWER 45 OF 61 PCTFULL COPYRIGHT 2002 Univentio

ACCESSION NUMBER: 2000078972 PCTFULL ED 20020515

TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR INCREASING CHOLESTEROL EFFLUX AND RAISING HDL USING ATP BINDING CASSETTE TRANSPORTER PROTEIN ABC1

TITLE (FRENCH): COMPOSITIONS ET PROCEDES VISANT A AUGMENTER LA SORTIE DE CHOLESTEROL ET A AUGMENTER LA HDL AU MOYEN DE LA PROTEINE DE TRANSPORT DE CASSETTES DE LIAISON D'ATP ABC1

INVENTOR(S): LAWN, Richard, M.; WADE, David; GARVIN, MichaelRP : HUGHES, A., Blair

PATENT ASSIGNEE(S): CV THERAPEUTICS, INC.; LAWN, Richard, M.; WADE, David; GARVIN, Michael

LANGUAGE OF FILING: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 2000078972	A2	20001228
DESIGNATED STATES	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2000-US16765	A	20000616
PRIORITY INFO.:	US 1999-60/140,264		19990618
	US 1999-60/153,872		19990914
	US 1999-60/166,573		19991119

ABEN The present invention relates to novel ABC1 polypeptides and nucleic

acid molecules encoding
the same. The invention also relates to recombinant vectors, host cells, and compositions comprising
ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also
relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention
relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1
expression and activity. The present invention further relates to methods for identifying compounds
that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1
polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits
and compositions suitable for screening compounds to determine the ABC1 expression modulating
activity of the compound, as well as kits and compositions suitable to determine whether a compound
modulates ABC1-dependent cholesterol efflux.

ABFR L'invention concerne de nouveaux polypeptides ABC1 et des molecules d'acides nucleiques codant
pour eux. Elle concerne aussi des vecteurs recombinants, des cellules cibles et des compositions
comprenant des polynucleotides ABC1 ainsi que des procedes destines a la fabrication de polypeptides
ABC1. De meme, l'invention concerne des anticorps qui se lient specifiquement aux polypeptides ABC1.
En outre, elle concerne des procedes pour augmenter la sortie de cholesterol et des procedes pour
intensifier l'expression et l'activite des ABC1. L'invention concerne des procedes pour identifier
les composes qui modulent l'expression des ABC1 et des procedes pour detecter le taux comparatif de
polypeptides et de polynucleotides ABC1 chez un sujet mammifere. Elle decrit des kits et des
compositions utilisables pour cribler des composes afin de determiner l'activite de modulation de
l'expression d'ABC1 dans un compose donne ainsi que des kits et des compositions permettant de
determiner si un compose module la sortie de cholesterol dependant d'ABC1.

L28 ANSWER 46 OF 61 PCTFULL COPYRIGHT 2002 Univentio
ACCESSION NUMBER: 2000078971 PCTFULL ED 20020515
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR INCREASING CHOLESTEROL EFFLUX AND RAISING HDL USING ATP BINDING CASSETTE TRANSPORTER PROTEIN ABC1
TITLE (FRENCH): COMPOSITIONS ET PROCEDES VISANT A AUGMENTER LA SORTIE DE CHOLESTEROL ET A AUGMENTER LA HDL AU MOYEN DE LA PROTEINE DE TRANSPORT DE CASSETTES DE LIAISON D'ATP ABC1
INVENTOR(S): LAWN, Richard, M.; WADE, David; ORAM, John, F.; GARVIN, MichaelRP : HUGHES, A., Blair
PATENT ASSIGNEE(S): CV THERAPEUTICS, INC.; UNIVERSITY OF WASHINGTON; LAWN, Richard, M.; WADE, David; ORAM, John, F.; GARVIN, Michael
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000078971	A2	20001228

DESIGNATED STATES AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE

DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG
ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI
FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN
GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-US16591 A 20000616
PRIORITY INFO.: US 1999-60/140,264 19990618
US 1999-60/153,872 19990914
US 1999-60/166,573 19991119

ABEN The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.

ABFR L'invention concerne de nouveaux polypeptides ABC1 et des molecules d'acides nucleiques codant pour eux. Elle concerne aussi des vecteurs recombinants, des cellules cibles et des compositions comprenant des polynucleotides ABC1 ainsi que des procedes destines a la fabrication de polypeptides ABC1. De meme, l'invention concerne des anticorps qui se lient specifiquement aux polypeptides ABC1. En outre, elle concerne des procedes pour augmenter la sortie de cholesterol et des procedes pour intensifier l'expression et l'activite des ABC1. L'invention concerne des procedes pour identifier les composes qui modulent l'expression des ABC1 et des procedes pour detecter le taux comparatif de polypeptides et de polynucleotides ABC1 chez un sujet mammalien. Elle decrit des kits et des compositions utilisables pour cribler des composes afin de determiner l'activite de modulation de l'expression d'ABC1 dans un compose donne ainsi que des kits et des compositions permettant de determiner si un compose module la sortie de cholesterol dependant d'ABC1.

L28 ANSWER 47 OF 61 USPATFULL
ACCESSION NUMBER: 2000:87939 USPATFULL
TITLE: Compositions that specifically bind to colorectal cancer cells and methods of using the same
INVENTOR(S): Waldman, Scott A., Ardmore, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

NUMBER KIND DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6087109		20000711
APPLICATION INFO.:	US 1998-193997		19981117 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-467920, filed on 6 Jun 1995, now patented, Pat. No. US 5962220, issued on 5 Oct 1999 which is a continuation-in-part of Ser. No. US 1993-141892, filed on 26 Oct 1993, now patented, Pat. No. US 5518888, issued on 21 May 1996

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Houtteman, Scott W.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 1787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed. Pharmaceutical compositions which comprise conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed including pharmaceutical compositions that have enteric formulations. Methods of treating an individual suspected of suffering from colorectal cancer and methods of preventing colorectal cancer are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 48 OF 61 USPATFULL

ACCESSION NUMBER: 2000:117522 USPATFULL
TITLE: Methods to express genes from viral vectors
INVENTOR(S): Dropulic, Boro, Ellicott City, MD, United States
Pitha, Paula M., Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6114141		20000905
APPLICATION INFO.:	US 1999-251085		19990216 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-917625, filed on 22 Aug 1997, now patented, Pat. No. US 5888767 which is a division of Ser. No. US 1996-758598, filed on 27 Nov 1996, now patented, Pat. No. US 5885806

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-32800P	19951128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schwartzman, Robert A.
ASSISTANT EXAMINER: Larson, Thomas G.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 2876
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection,

and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 49 OF 61 USPATFULL
ACCESSION NUMBER: 2000:113694 USPATFULL
TITLE: Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
INVENTOR(S): Grosveld, Franklin Gerardus, Rotterdam, Netherlands
Ellis, James, Toronto, Canada
Kioussis, Dimitris, London, United Kingdom
PATENT ASSIGNEE(S): Medical Research Council, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6110666		20000829	
APPLICATION INFO.:	US 1995-488145		19950607	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-314657, filed on 29 Sep 1994, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-11618	19940609

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
LEGAL REPRESENTATIVE: Williams Ph.D., Kathleen M.Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 2783
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention encompasses a locus control subregion that possesses chromatin opening domain activity, the activity conferring reproducible activation of tissue-specific expression on a linked transgene to a non-physiological level when the transgene is integrated in single copy in the genome of a host cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 50 OF 61 USPATFULL
ACCESSION NUMBER: 2000:80583 USPATFULL
TITLE: Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
INVENTOR(S): Heidtmann, Hans Heinrich, Marburg, Germany, Federal Republic of
Mueller, Rolf, Marburg, Germany, Federal Republic of
Sedlacek, Hans-Harald, Marburg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft AG, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6080575		20000627	
APPLICATION INFO.:	US 1998-8308		19980116	(9)

	NUMBER	DATE

PRIORITY INFORMATION:	DE 1997-19701141	19970116
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hutzell, Paula K.	
ASSISTANT EXAMINER:	Sun-Hoffman, Lin	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	2578	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B) c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 51 OF 61 USPATFULL

ACCESSION NUMBER:	2000:77463 USPATFULL		
TITLE:	Mediators of chronic allograft rejection (AIF-1) and DNA encoding them		
INVENTOR(S):	Russell, Mary E., Carlisle, MA, United States Utans, Ulrike, Grenzach-Wyhlen, Germany, Federal Republic of		
PATENT ASSIGNEE(S):	President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6077948		20000620
APPLICATION INFO.:	US 1994-361441		19941221 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-171385, filed on 21 Dec 1993, now patented, Pat. No. US 5527884		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Draper, Garnette D.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	53 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	2982		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Differentially expressed allograft genes, methods of screening therefor, and methods of diagnosing and treating allograft rejection and other conditions related to vascular inflammation, such as atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 52 OF 61 USPATFULL

ACCESSION NUMBER:	2000:53886 USPATFULL
TITLE:	HIV coreceptor mutants
INVENTOR(S):	Landau, Nathaniel R., New York, NY, United States Koup, Richard A., Southlake, TX, United States Liu, Rong, New York, NY, United States

PATENT ASSIGNEE(S):	Paxton, William, Amsterdam, Netherlands The Aaron Diamond Aids Research Center, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057102		20000502
APPLICATION INFO.:	US 1997-907468		19970808 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25230P	19960808 (60)
	US 1996-17157P	19960520 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Budens, Robert D.
LEGAL REPRESENTATIVE:	Klauber & Jackson
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT:	3236

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta.. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 53 OF 61 MEDLINE DUPLICATE 1

ACCESSION NUMBER:	2000477552 MEDLINE
DOCUMENT NUMBER:	20479893 PubMed ID: 11028922
TITLE:	Highly efficient cell-mediated gene transfer using non-viral vectors and FuGene6: in vitro and in vivo studies.
AUTHOR:	Hellgren I; Drvota V; Pieper R; Enoksson S; Blomberg P; Islam K B; Sylven C
CORPORATE SOURCE:	Department of Cardiology, The Clinical Research Center, Huddinge, Stockholm, Sweden.. irina.hellgren@medhs.ki.se
SOURCE:	CELLULAR AND MOLECULAR LIFE SCIENCES, (2000 Aug) 57 (8-9) 1326-33. Journal code: 9705402. ISSN: 1420-682X.
PUB. COUNTRY:	Switzerland
DOCUMENT TYPE:	Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:	English
FILE SEGMENT:	Priority Journals
ENTRY MONTH:	200011
ENTRY DATE:	Entered STN: 20010322 Last Updated on STN: 20010322 Entered Medline: 20001103

AB The present study was undertaken to develop an efficient non-viral **gene delivery** system for cardiovascular gene therapy. We investigated transfection efficiency and toxic properties of the new transfection reagent, FuGene6, and compared it with two other transfection reagents, Tfx-50 and LipoTaxi. For in vivo experiments, the plasmid was

delivered intramuscularly via transplantation of fibroblasts transfected with plasmid and FuGene6. Conditions for efficient **gene delivery** were initially studied in vitro. Human and rabbit fibroblasts were isolated from skin, cultured and transfected with phVEGF165 or pCMVbeta gal plasmids, coding for vascular endothelial growth factor (VEGF) or beta-galactosidase, respectively. The effect of the DNA amount and the DNA:transfection reagent ratio on plasmid uptake were studied. Of the transfection reagents tested, only FuGene6 provided high-efficiency and dose-dependent plasmid transfer both for cell-localised (beta-galactosidase) and secreted (VEGF) gene products. When analysed with an MTT assay, FuGene6 showed no toxicity at low doses. Optimised conditions were applied for in vivo reporter **gene delivery**. Rabbits were injected intramuscularly with ex vivo-transfected fibroblasts. As in in vitro studies, ex vivo-transfected fibroblasts showed highly efficient gene expression in vivo. Tissue sections were analysed with **macrophage-specific** immunostaining. No signs of inflammation were seen in the region of fibroblast injection. This study demonstrates that FuGene6 is a highly efficient transfection reagent that may be useful for in vitro non-viral transfection of primary human and rabbit fibroblasts and for in vivo therapeutic non-viral **gene delivery**.

L28 ANSWER 54 OF 61 USPATFULL

ACCESSION NUMBER:	1999:121123 USPATFULL
TITLE:	Compositions that specifically bind to colorectal cells and methods of using the same
INVENTOR(S):	Waldman, Scott A., Ardmore, PA, United States
PATENT ASSIGNEE(S):	Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962220		19991005
APPLICATION INFO.:	US 1995-467920		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-141892, filed on 26 Oct 1993, now patented, Pat. No. US 5518888		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Houtteman, Scott W.		
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris, LLP		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1515		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed. Pharmaceutical compositions which comprise conjugated compounds that comprise an ST receptor binding moiety and an active moiety that is an antisense molecule are disclosed including pharmaceutical compositions that have enteric formulations. Methods of treating an individual suspected of suffering from colorectal cancer and methods of preventing colorectal cancer are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 55 OF 61 USPATFULL

ACCESSION NUMBER:	1999:166982 USPATFULL
TITLE:	Methods for treating arthritis by administering an apoptosis regulator
INVENTOR(S):	Firestein, Gary S., Del Mar, CA, United States Zvaifler, Nathan J., La Jolla, CA, United States Green, Douglas R., San Diego, CA, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6004942		19991221	
APPLICATION INFO.:	US 1996-705243		19960830	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-2948P	19950830 (60)
	US 1996-16316P	19960426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Gray, Cary, Ware & Freidenrich, LLP, Haile, Ph.D., Lisa A.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes **gene delivery** and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods for detecting cellular accumulation diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 56 OF 61 USPATFULL
ACCESSION NUMBER: 1999:150906 USPATFULL
TITLE: Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
INVENTOR(S): Tabas, Ira, New City, NY, United States
Schissel, Scott L., Teaneck, NJ, United States
Williams, Kevin Jon, Wynnewood, PA, United States
PATENT ASSIGNEE(S): The Trustees of Columbia University in the City of New York, New York, NY, United States (U.S. corporation)
Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5989803		19991123	
APPLICATION INFO.:	US 1997-937234		19970908	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lankford, Jr., Leon B.
ASSISTANT EXAMINER: Tate, Christopher R.
LEGAL REPRESENTATIVE: White, John P.Cooper & Dunham LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 3580
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides for a method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingmyelinase inhibitor effective to decrease extracellular zinc sphingomyelinase activity in the subject and thereby treat the subject. The present invention also provides for a method for determining whether a compound inhibits an activity of an extracellular

zinc sphingomyelinase involving ceramide formation which comprises: (a) contacting a sample containing the zinc sphingomyelinase under acidic pH conditions known to be associated with the activity of such zinc sphingomyelinase, with: (i) a substrate of the zinc sphingomyelinase enzyme, and (ii) the compound being evaluated; (b) measuring the concentration of ceramide in the sample from (a); (c) determining the amount of zinc sphingomyelinase activity in the sample based upon the concentration of ceramide measured in step (b); and (d) comparing the amount of sphingomyelinase activity determined in step (c) with the amount of sphingomyelinase activity determined in the absence of the compound, so as to determine whether the compound inhibits the activity of zinc sphingomyelinase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 57 OF 61 USPATFULL

ACCESSION NUMBER:	1999:96271 USPATFULL
TITLE:	G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
INVENTOR(S):	Littman, Dan R., New York, NY, United States Deng, Hongkui, New York, NY, United States Ellmeier, Wilfried, New York, NY, United States Landau, Nathaniel R., New York, NY, United States Liu, Rong, New York, NY, United States
PATENT ASSIGNEE(S):	New York University, New York, NY, United States (U.S. corporation) The Aaron Diamond Aids Research Center, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939320		19990817
APPLICATION INFO.:	US 1996-666020		19960619 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-650412, filed on 20 May 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-17157P	19960520 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Saunders, David
ASSISTANT EXAMINER:	VanderVegt, F. Pierre
LEGAL REPRESENTATIVE:	Klauber & Jackson
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT:	2091

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 58 OF 61 USPATFULL

ACCESSION NUMBER:	1999:40189 USPATFULL
TITLE:	Method of using a conditionally replicating viral

vector to express a gene
INVENTOR(S): Dropulic , Boro, Ellicott City, MD, United States
Pitha, Paula M., Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5888767		19990330
APPLICATION INFO.:	US 1997-917625		19970822 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-758598, filed on 27 Nov 1996

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-32800P	19951125 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Larson, Thomas
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 59 OF 61 USPATFULL
ACCESSION NUMBER: 1999:36929 USPATFULL
TITLE: Methods to prepare conditionally replicating viral vectors
INVENTOR(S): Dropulic , Boro, Ellicott City, MD, United States
Pitha, Paula M., Baltimore, MD, United States
PATENT ASSIGNEE(S): The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5885806		19990323
APPLICATION INFO.:	US 1996-758598		19961127 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Larson, Thomas
LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a conditionally replicating viral vector,

methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to viral vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 60 OF 61 USPATFULL

ACCESSION NUMBER:	1998:135025 USPATFULL
TITLE:	Cationic lipid: DNA complexes for gene targeting
INVENTOR(S):	Gorman, Cori M., San Francisco, CA, United States McClarrinon, Molly, San Francisco, CA, United States
PATENT ASSIGNEE(S):	Megabios Corporation, Burlingame, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5830878		19981103	
APPLICATION INFO.:	US 1995-485005		19950607	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Rories, Charles C. P.
LEGAL REPRESENTATIVE:	McDonnell, Boehnen Hulbert & Berghoff
NUMBER OF CLAIMS:	9
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT:	1364

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention herein describes pharmaceutical compositions and methods for targeted delivery of functional genes into cells and tissues in vivo. The invention discloses DNA:lipid complexes, methods of making such complexes and methods of using such complexes for facilitating the targeted delivery and entry of recombinant expression constructs into cells and tissues in vivo, and particularly delivery of such recombinant expression constructs by intravenous, intraperitoneal or direct injection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28 ANSWER 61 OF 61 USPATFULL

ACCESSION NUMBER:	96:53399 USPATFULL
TITLE:	Mediators of chronic allograft rejection and DNA molecules encoding them
INVENTOR(S):	Russell, Mary E., Carlisle, MA, United States Utans, Ulrike, Cambridge, MA, United States
PATENT ASSIGNEE(S):	President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5527884		19960618	
APPLICATION INFO.:	US 1993-171385		19931221	(8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Allen, Marianne P.
LEGAL REPRESENTATIVE:	Fish & Richardson
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 21 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Differentially expressed allograft genes, methods of screening therefor, and methods of diagnosing and treating allograft rejection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.